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SOMATIC GENOME EDITING IN SICKLE CELL 
DISEASE: REWRITING A MORE JUST FUTURE* 
VENCE L. BONHAM** & LISA E. SMILAN*** 
Genome-editing technologies promise novel therapies for 
hematologic disorders. Sickle cell disease (“SCD”), the most 
common inherited blood disorder, has been identified as one 
condition where somatic genome editing may provide a cure to 
alleviate the burden and suffering of the disease. SCD has been 
slated as one of the first targets for Phase I clinical trials. Given 
the legacy of discrimination and health inequities for individuals 
living with the disease and individuals living with sickle cell trait 
(“SCT”), carriers of one sickle cell gene, policymakers and 
scientists developing genome-editing research and clinical 
programs must consider the history of SCD. This Article surveys 
the social and legal context of SCD and current somatic genome-
editing research. It maintains that development and access to 
curative genetic therapies should be based on the principle of 
fairness. Equitable application of human genome editing must 
serve as the core legal, ethical, and social compass that guides the 
implementation of somatic genome-editing research and clinical 
treatment. Proactive steps must be taken to ensure that SCD 
globally is not left behind in the development of genome-editing 
technologies. 
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INTRODUCTION 
Approximately 1,000 children in Africa are born with SCD every 
day and more than half will die before they reach five.1 
In 1910, Dr. James Herrick described a blood cell irregularity in 
his article, “Peculiar Elongated and Sickle-Shaped Red Blood 
Corpuscles in a Case of Severe Anemia,” in the Archives of Internal 
Medicine: this “peculiar” phenomenon later came to be known as 
SCD.2 The identification of this disease within the Western medical 
community was an important milestone in the science of human 
genetics. Today, SCD is used to describe several inherited blood 
disorders, including sickle cell anemia, HbSC, and HbSβ-
thalassaemia.3 Throughout the history of SCD—the most common 
single-gene disease—treatment of this community has been 
intertwined with race and inequities in health care. 
While the pharmacological revolution of the last twenty-five 
years failed to benefit the SCD community, during the last five years 
promising new drugs and genetic curative treatments have emerged.4 
While acknowledging the promise and potential of novel genetic 
therapies to end suffering of those with SCD, this Article considers 
the historical context of the disease and how that history affects 
current ethical, legal, and social implications of the research. 
The National Academies of Sciences, Engineering, and Medicine 
2017 Report on Human Genome Editing identifies fairness as an 
important principle, requiring  
that like cases be treated alike, and that risks and benefits be 
equitably distributed (distributive justice). Responsibilities that 
flow from adherence to this principle include (1) equitable 
distribution of the burdens and benefits of research and (2) 
 
 1. AM. SOC’Y OF HEMATOLOGY, STATE OF SICKLE CELL DISEASE: 2016 REPORT 
22 (2016), http://www.scdcoalition.org/pdfs/ASH%20State%20of%20Sickle%20Cell%
20Disease%202016%20Report.pdf [https://perma.cc/KQ7E-372W]. 
 2. James B. Herrick, Peculiar Elongated and Sickle-Shaped Red Blood Corpuscles in 
a Case of Severe Anemia, 5 ARCHIVES INTERNAL MED. 517 (1910), reprinted in 74 YALE 
J. BIOLOGY & MED. 179, 179 & cmt. a (2001). 
 3. Catherine Booth, Baba Inusa & Stephen K. Obaro, Infection in Sickle Cell 
Disease: A Review, 14 INT’L J. INFECTIOUS DISEASES e2, e2–e3 (2010). 
 4. See, e.g., Chris Morris, The Story Behind the New Sickle Cell Drug That Was 25 
Years in the Making, CNBC (Aug. 7, 2017, 9:58 AM), https://www.cnbc.com/2017/08/07/
new-sickle-cell-anemia-drug-endari-by-emmanus-is-fda-approved.html [https://perma.cc/
N9QY-R2JD]. 
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broad and equitable access to the benefits of resulting clinical 
applications of human genome editing.5  
Fairness, which includes equitable access, must be at the forefront in 
developing both policies and clinical trials. The commitment of every 
stakeholder engaged in the research, development, production, and 
provision of the new technology will be required to address this 
challenging goal—essentially, that grand scientific advances in 
biotechnology must translate into health care for underserved 
patients. The pharmaceuticals industry, government regulators and 
policymakers, legislators, bioethicists, health-care professionals, and 
insurers cannot operate in isolation; each must invite the voices of 
patients and their advocates to join in collaborative dialogue and 
policymaking. 
This Article describes the discrimination that SCD patients have 
faced in the past and proposes a fairness-based framework to guide 
future treatment and research to ensure equitable access to somatic 
gene editing in the SCD community.6 Part I of the Article discusses 
current advances in gene editing and its potential to cure disease. Part 
II provides an overview of SCD and how somatic genome editing may 
someday cure individuals with the disease. Part III contemplates the 
legacy of discrimination endured by the SCD community, which may 
inform the community’s concerns regarding inequitable access to new 
treatments. Part IV considers the importance of engaging in 
 
 5. NAT’L ACADS. OF SCIS., ENG’G, & MED., HUMAN GENOME EDITING: SCIENCE, 
ETHICS, AND GOVERNANCE 12 (2017); see also NAT’L COMM’N FOR THE PROT. OF 
HUMAN SUBJECTS OF BIOMEDICAL & BEHAVIORAL RESEARCH, THE BELMONT 
REPORT: ETHICAL PRINCIPLES AND GUIDELINES FOR THE PROTECTION OF HUMAN 
SUBJECTS OF RESEARCH 10, https://videocast.nih.gov/pdf/ohrp_belmont_report.pdf 
[https://perma.cc/NND4-RLRY] (“[W]henever research supported by public funds leads 
to the development of therapeutic devices and procedures, justice demands both that 
these not provide advantages only to those who can afford them and that such research 
should not unduly involve persons from groups unlikely to be among the beneficiaries of 
subsequent applications of the research.”).  
 6. Somatic Genome Editing is  
the alteration of cells that cannot contribute to gamete formation and thus cannot 
be passed on from the individual to offspring. In contrast, germline genome 
editing, .	.	. refers to genome editing that occurs in a germ cell or embryo and 
results in changes that are theoretically present in all cells of the embryo and that 
could also potentially be passed from the modified individual to offspring. In 
theory, modification of gamete-producing cells at any point in development could 
permit this. Because human germline genome editing has potential effects on both 
the treated individual and subsequent generations of persons, it entails ethical 
considerations beyond those of somatic genome modification.  
Kelly E. Ormond et al., Human Germline Genome Editing, 101 AM. J. HUM. GENETICS 
167, 169 (2017). 
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conversations with the SCD community about its thoughts, beliefs, 
hopes, and fears relating to curative genetic therapies and how such 
engagement may forestall perpetual health inequities. Part V provides 
an overview of current legal protections relating to genetic 
information and its limitations concerning diagnosed genetic diseases. 
Part VI considers the idea of equity and gene editing, spotlighting 
new approaches to ensure inclusion and affordability for the SCD 
community. 
I.  GENOME EDITING AND THE POTENTIAL OF CURING DISEASE 
Genome editing is a “group of [techniques] that give scientists 
the ability to change an organism’s” genome by removal or change in 
genetic material, specifically deoxyribonucleic acid (“DNA”) or 
ribonucleic acid (“RNA”).7 In humans, a vector to edit a gene can 
either be delivered outside the body (ex vivo treatment) or the 
vectors can be injected into the body (in vivo treatment).8 These 
techniques “allow genetic material to be added, removed, or altered 
at particular locations in the genome.”9 
In 2012, Jennifer Doudna, Emmanuelle Charpentier, and their 
colleagues published a groundbreaking report on how Clustered 
Regularly Interspaced Short Palindromic Repeats (“CRISPR”), when 
combined with an enzyme called CRISPR protein 9 (“Cas9”), could 
be programmed to edit the DNA of virtually any living organism.10 
Enthusiasm about CRISPR—a naturally occurring, ancient defense 
mechanism deployed by bacteria to destroy invading viruses—stems 
from its precision and low cost relative to comparable techniques.11 
Feng Zhang and his colleagues were the first to use genome-editing 
techniques in eukaryotic cells including human cells.12 In 2015, Science 
named CRISPR as the “Breakthrough of the Year,” describing it as a 
“molecular marvel” and recognizing the exponential growth in the 
 
 7. What Are Genome Editing and CRISPR-Cas9?, NIH: GENETICS HOME 
REFERENCE, https://ghr.nlm.nih.gov/primer/genomicresearch/genomeediting [https://perma.cc/
JHJ6-E7VV] (last updated Apr. 30, 2019). 
 8. How Does Gene Therapy Work?, NIH: GENETICS HOME REFERENCE, 
https://ghr.nlm.nih.gov/primer/therapy/procedures [https://perma.cc/63KF-66VV] (last 
updated Apr. 30, 2019). 
 9. What Are Genome Editing and CRISPR-Cas9?, supra note 7. 
 10. Martin Jinek et al., A Programmable Dual-RNA-Guided DNA Endonuclease in 
Adaptive Bacterial Immunity, 337 SCIENCE 816, 816 (2012). 
 11. Id.; see also Mark Shwartz, Target, Delete, Repair, STAN. MED., Winter 2018, at 20, 
27 (explaining that “CRISPR has made gene editing cheap, easy and accessible”). 
 12. Le Cong et al., Multipex Genome Engineering Using CRISPR/Cas Systems, 339 
SCIENCE 819, 820 (2013). 
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scientific community’s understanding of the tool and how it could be 
applied within various clinical, environmental, and ecological 
contexts.13 
The medical utility of CRISPR gene editing has continued to 
develop at a rapid pace. In 2016, doctors in China began using 
CRISPR-Cas9 to edit immune cells from lung cancer patients to 
inactivate the protein PD-1, which therefore made immunotherapy 
more effective.14 In mid-2017, researchers successfully used a 
variation of the CRISPR tool to correct the mutation underlying 
Duchenne muscular dystrophy (“DMD”), both in patient-derived 
induced pluripotent stem cells (“iPSCs”) and in mdx mice (which 
have the same dystrophin mutation as human patients).15 Around the 
same time, another research team demonstrated, for the first time, the 
way in which CRISPR could be used to halt HIV-1 replication and 
eliminate the virus from infected cells in animal models.16 With the 
fast-moving development of the science, clinical trials are being 
developed to treat diseases using somatic genome editing.17 
The first somatic gene-editing clinical trials in the United States 
occurred in 2017, when the first U.S. patient received an in vivo zinc 
finger nucleases (“ZFNs”)-based editing therapy for Hunter 
syndrome (mucopolysaccharidosis type II).18 Additional genome-
editing trials using ZFNs are now open for other rare genetic 
conditions, such as mucopolysaccharidosis I,19 hemophilia B,20 and β-
thalassemia.21 
 
 13. John Travis, Making the Cut: CRISPR Genome-Editing Technology Shows Its 
Power, 350 SCIENCE 1456, 1456–57 (2015). 
 14. David Cyranoski, CRISPR Gene Editing Tested in a Person, 539 NATURE 479, 479 
(2016).  
 15. Yu Zhang et al., CRISPR-Cpf1 Correction of Muscular Dystrophy Mutations in 
Human Cardiomyocytes and Mice, 3 SCI. ADVANCES, no. e1602814, Apr. 12, 2017, at 1, 1. 
 16. Ramona Bella et al., Removal of HIV DNA by CRISPR from Patient Blood 
Engrafts in Humanized Mice, 12 MOLECULAR THERAPY: NUCLEIC ACIDS 275, 275 
(2018). 
 17. Martina C. Cornel et al., Moving Towards a Cure in Genetics: What Is Needed to 
Bring Somatic Gene Therapy to the Clinic?, 27 EUR. J. HUM. GENETICS 484, 484 (2019). 
 18. Jocelyn Kaiser, A Human Has Been Injected with Gene-Editing Tools to Cure 
His Disabling Disease. Here’s What You Need to Know, SCIENCE (Nov. 15, 2017, 6:00 
PM), https://www.sciencemag.org/news/2017/11/human-has-been-injected-gene-editing-
tools-cure-his-disabling-disease-here-s-what-you [https://perma.cc/6T23-TP49]. 
 19. Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) 
Therapeutic SB-318 in Subjects with MPS I, CLINICALTRIALS.GOV, 
https://clinicaltrials.gov/ct2/show/NCT02702115 [https://perma.cc/2T3W-4HH2] (last 
updated June 7, 2018). 
 20. Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic 
SB-FIX in Subjects with Severe Hemophilia B, CLINICALTRIALS.GOV, 
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The discovery of the CRISPR-Cas9 system for genome editing, 
and its application to human cells, has accelerated progress in genome 
editing.22 The first U.S.-based CRISPR-Cas9 clinical trial began 
recruiting cancer patients for an ex vivo approach in 2018.23 The 
eagerly awaited results from these clinical trials will act as the first 
indications of the safety and efficacy of CRISPR-Cas9 genome-
editing approaches.24 Trials using both ZFNs and CRISPR-Cas9 gene 
editing are in the pipeline for SCD.  
II.  SCD AND SOMATIC GENOME EDITING 
As gene-editing technology advances, it becomes more likely 
that a technique like CRISPR can be used to develop a cure for SCD. 
This part provides an overview of SCD, the genome-editing-based 
approaches being developed to treat it, and the reaction of the SCD 
community to these new approaches. 
A. Background of SCD 
SCD is the most common monogenic disorder, caused by a 
single-point mutation.25 This mutation is located in the sixth codon of 
 
https://clinicaltrials.gov/ct2/show/NCT02695160 [https://perma.cc/7EUJ-3XER] (last 
updated Feb. 12, 2019).  
 21. A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of 
Transfusion-Dependent Beta-thalassemia (TDT), CLINICALTRIALS.GOV, 
https://clinicaltrials.gov/ct2/show/NCT03432364?term=genome+editing&rank=6 [https://perma.cc/
UCS6-7VEE] (last updated Feb. 4, 2019). 
 22. Jennifer A. Doudna & Emmanuelle Charpentier, The New Frontier of Genome 
Engineering with CRISPR-Cas9, 346 SCIENCE 1077, 1077 (2014). 
 23. NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T 
Cells), CLINICALTRIALS.GOV, https://clinicaltrials.gov/ct2/show/NCT03399448 [https://perma.cc/
F6V6-YZLQ] (last updated Mar. 4, 2019). 
 24. See Mary Ellen Perry et al., Genome Editing to ‘Re-Write’ Wrongs, 17 NATURE 
REVIEWS: DRUG DISCOVERY 689, 689–90 (2018). The range of potential applications 
makes the results of particular interest: 
The relative ease of targeting by interchangeable guide RNAs is likely to be 
particularly important for rare monogenic diseases. There are thousands of such 
diseases, and each can result from different mutations in different individuals. 
Following the discovery of Cas9, researchers have identified homologues in other 
species with improved properties, such as reduced size and increased specificity. In 
addition, engineered versions of Cas9 and related proteins, including nuclease-free 
versions of Cas9 coupled to DNA or RNA-modifying enzymes, have been 
developed. Of note are base editors that can correct the most common disease-
causing single-base mutations without creating a double-strand break in DNA. 
Id. at 689.  
 25. Frédéric B. Piel, Martin H. Steinberg & David C. Rees, Sickle Cell Disease, 376 
NEW ENG. J. MED. 1561, 1561 (2017) [hereinafter Piel et al., Sickle Cell Disease]. 
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the β-hemoglobin subunit.26 SCD is “a group of inherited diseases .	.	. 
characterized by mutations in the gene encoding the hemoglobin 
subunit β (HBB).”27 Sickle erythrocytes, or red blood cells, can lead 
to recurrent vaso-occlusive episodes that are the hallmark of the 
disease.28 
The burden of the disease is highest in sub-Saharan Africa; 
however, the disease is also common in the Mediterranean basin, 
the Middle East, and India.29 The prevalence is estimated to be 
between 300,000 and 400,000 infants born globally each year, the 
majority in sub-Saharan Africa.30 It is also estimated that 100,000 
people in the United States live with the disease.31 Individuals living 
with SCD with the same genotype can clinically present very 
differently.32 Common complications are acute pain events, acute 
chest syndrome, stroke, leg ulcers, priapism, and sickle cell 
retinopathy.33 The disease burden on the body can result in end 
organ damage.34 
The number of individuals living with the disease is expected to 
increase globally.35 In high-income countries, this increase reflects 
migration36 and gains in life expectancy among affected persons in 
these countries that result from health interventions such as newborn 
screening, penicillin prophylaxis, pneumococcal immunization, and 
education about disease complications.37 In many African countries, 
where the frequency is the highest, the overall number of births is 
expected to double between 2010 and 2050.38 Worldwide, the growth 
in the number of babies born with the disease is expected to increase 
 
 26. Nicola Conran, Carla F. Franco-Penteado & Fernando F. Costa, Newer Aspects of 
the Pathophysiology of Sickle Cell Disease Vaso-Occlusion, 33 HEMOGLOBIN 1, 1 (2009). 
 27. Gregory J. Kato et al., Sickle Cell Disease, 4 NATURE REVIEWS: DISEASE 
PRIMERS, no. 18010, Mar. 15, 2018, at 1, 1. 
 28. Piel et al., Sickle Cell Disease, supra note 25, at 1565. 
 29. Kato et al., supra note 27, at 2. 
 30. Frédéric B. Piel et al., Global Burden of Sickle Cell Anaemia in Children Under 
Five, 2010–2050: Modelling Based on Demographics, Excess Mortality, and Interventions, 
10 PLOS MED., no. e1001484 July 2013, at 1, 4 [hereinafter Piel et al., Global Burden]. 
 31. See Sickle Cell Disease, CENTERS FOR DISEASE CONTROL & PREVENTION, 
https://www.cdc.gov/ncbddd/sicklecell/data.html [https://perma.cc/L54L-9CJC]. 
 32. Kato et al., supra note 27, at 11. 
 33. Id. at 1, 3, 4. 
 34. Id. at 5. 
 35. Piel et al., Global Burden, supra note 30, at 4. 
 36. Stephan Lobitz et al., Newborn Screening for Sickle Cell Disease in Europe: 
Recommendations from a Pan-European Consensus Conference, 183 BRIT. J. 
HAEMATOLOGY 183, 648, 650 (2018).  
 37. Russell E. Ware et al., Sickle Cell Disease, 390 LANCET 311, 311 (2017).  
 38. Piel et al., Global Burden, supra note 30, at 4. 
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by more than 30% by 2050.39 Currently, in low-income countries, 90% 
of children with SCD do not survive to adulthood.40 
The molecular basis of SCD has been studied for many years and 
is well understood. While a cure exists in the form of hematopoietic 
stem cell transplantation (“HSCT”), it can be difficult to find donor 
matches.41 Furthermore, HSCT remains an expensive procedure with 
the prospect of serious complications, such as graft versus host disease 
(“GVHD”).42 The limitations of treatments and procedures like 
HSCT combined with the devastating nature of SCD and documented 
poor access to high-quality care, has sparked hope that the era of 
gene editing and gene therapy will change the tide for patients who 
have historically been disenfranchised by the biomedical system.43 
Recent improvements in understanding the molecular pathways 
controlling production of red blood cells and fetal-to-adult 
hemoglobin switching offer new therapeutic options.44 Substantial 
resources are being directed into discovering a gene-editing cure 
using these new mechanisms.45 To this end, SCD may facilitate a 
turning point for gene-editing and gene-therapy research.  
B. SCD and Genome Editing 
There are two dominant genome-editing approaches under 
current exploration for treatment of SCD.46 The first, described as 
“[t]he holy grail of genome editing for the β-hemoglobinopathies[,] is 
the correction of the β-globin mutation .	.	.	.”47 Using CRISPR-Cas9 to 
repair the β-globin gene, preclinical studies have successfully used a 
viral approach to edit hematopoietic stem cells from patients with 
 
 39. Id.  
 40. AM. SOC’Y OF HEMATOLOGY, supra note 1, at 23. 
 41. Courtney D. Fitzhugh et al., Hematopoietic Stem Cell Transplantation for Patients 
with Sickle Cell Disease: Progress and Future Directions, 28 HEMATOLOGY/ONCOLOGY 
CLINICS N. AM. 1171, 1178 (2014). 
 42. Javier Bolaños-Meade & Robert A. Brodsky, Blood and Marrow Transplantation 
for Sickle Cell Disease: Overcoming Barriers to Success, 21 CURRENT OPINION 
ONCOLOGY 158, 158 (2009). 
 43. Katherine Bourzac, Erasing Sickle-Cell Disease, NATURE OUTLOOK: BLOOD, 
Sept. 28, 2017, at S28, S30.  
 44. Selami Demirci, Naoya Uchida & John F. Tisdale, Gene Therapy for Sickle Cell 
Disease: An Update, 20 CYTOTHERAPY 899, 899 (2018).  
 45. Edward J. Benz Jr., The Cure Sickle Cell Initiative: Catalyzing Progress via 
Innovative Interfaces Between NIH, Patients, Academics, ASH, and the Private Sector, 
HEMATOLOGIST, Nov.–Dec. 2018, at 1, 1. 
 46. Demirci et al., supra note 44, at 904.  
 47. Id.  
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SCD in the lab.48 The researchers have also shown that they can 
successfully transplant the repaired cells into blood stem cells of 
mice.49 
 


















            
 
 
Approach A: Schematic of β-globin mutation correction using 
CRISPR-Cas9. The correction is made by changing the single 
nucleotide mutation thymine to adenine (T to A), which 
changes glutamic acid to valine at codon 6 of the β-globin 
(HBB) gene. (Image Credit: Darryl Leja, National Human 
Genome Research Institute).  
The second approach entails disrupting BCL11A, a region of the 
DNA known to suppress the production of fetal hemoglobin, a form 
 
 48. Rasmus O. Bak, Daniel P. Dever & Matthew H. Porteus, CRISPR/Cas9 Genome 
Editing in Human Hematopoietic Stem Cells, 13 NATURE PROTOCOLS 358, 358 (2018). 
 49. See, e.g., id. at 363; Mark A. DeWitt et al., Selection-Free Genome Editing of the 
Sickle Mutation in Human Adult Hematopoietic Stem/Progenitor Cells, 8 SCI. 
TRANSLATIONAL MED., no. 360ra134, Oct. 12, 2016, at 1, 1. 
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of hemoglobin associated with reduced disease severity.50 In 1949, 
Janet Watson and colleagues reported that the blood of infants with 
SCD delayed sickling in comparison to the mothers’ blood.51 This was 
later determined to be caused by the high levels of fetal hemoglobin 
(“HbF”) in the infants’ blood.52 Genome-wide association studies 
identified that the BCL11A gene variant was strongly associated with 
modulating HbF levels.53 The BCL11A gene variant is a prime target 
for genome editing.54 Research studies in mouse models have 
established that perturbation of the BCL11A enhancer with gene 
editing can result in HbF levels to clinically ameliorate the disease.55 
	  
 
 50. Daniel E. Bauer et al., An Erythroid Enhancer of BCL11A Subject to Genetic 
Variation Determines Fetal Hemoglobin Level, 342 SCIENCE 253, 254 (2013). 
 51. Janet Watson, Albert W. Stahman & Francis P. Bilello, The Significance of the 
Paucity of Sickle Cells in Newborn Negro Infants, 215 AM. J. MED. SCI. 419 (1948), 
reprinted in 3 OBSTETRICAL & GYNECOLOGICAL SURV. 819, 819 (1949). 
 52. C. Lockard Conley et al., Negro Families in Baltimore, 21 BLOOD 261, 278 (1963); 
G. Stamatoyannopoulos et al., A New Form of Hereditary Persistence of Fetal Hemoglobin 
in Blacks and Its Association with Sickle Cell Trait, 46 BLOOD 683, 683 (1975). 
 53. Bauer et al., supra note 50, at 253. 
 54. Stuart H. Orkin & Daniel E. Bauer, Emerging Genetic Therapy for Sickle Cell 
Disease, 70 ANN. REV. MED. 257, 260 (2019). 
 55. Matthew C. Canver et al., BCL11A Enhancer Dissection by Cas9-Mediated in Situ 
Saturating Mutagenesis, 527 NATURE 192, 196 (2015); Vijay G. Sankaran et al., Human 
Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-Specific Repressor 
BCL11A, 322 SCIENCE 1839, 1839 (2008); Manuela Uda et al., Genome-Wide Association 
Study Shows BCL11A Associated with Persistent Fetal Hemoglobin and Amelioration of 
the Phenotype of β-thalassemia, 105 PNAS 1620, 1620 (2008). 
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Approach B: Schematic of gene editing to control silencing the 
BCL11A gene, a region of the DNA known to suppress the 
production of fetal hemoglobin. The use of CRISPR-Cas9 to 
disrupt BCL11A allows for the production of high levels of fetal 
hemoglobin (HbF; hemoglobin F) in red blood cells. (Image 
Credit: Darryl Leja, National Human Genome Research 
Institute)  
Besides these two novel approaches, other curative genetic 
therapies are moving forward. Sickle cell ex vivo gene therapy, 
inserting a normal, functional gene to replace an abnormal gene, can 
modify an individual’s genome.56 In March 2017, Jean-Antoine Ribeil 
and colleagues reported the results of the first SCD patient who 
received this therapy in France, stating that the patient achieved 
“complete clinical remission with correction of hemolysis and biologic 
 
 56. Orkin & Bauer, supra note 54, at 264.  
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hallmarks of the disease.”57 In that study, a research team endeavored 
to insert a functional β-globin into a patient’s hematopoietic stem 
cells, ex vivo, through the use of a lentiviral vector.58 This 
breakthrough, along with the decades of foundational study dedicated 
to understanding the molecular basis underlying this disease, may 
pave the path for SCD to lead the implementation of these new 
technologies into clinical care.59  
C. Cure for SCD and Engagement of the Community 
Disorders of the blood constitute an area of active gene-therapy 
and gene-editing research currently underway.60 In January 2018, the 
National Institutes of Health (“NIH”) launched a $190 million, six-
year research initiative to remove the implementation barriers of 
somatic gene editing in clinical care.61 These endeavors include 
improving current delivery mechanisms, genome editors, and assays 
for testing the safety and efficacy of genome-editing tools.62 With this 
program, the NIH hopes to accelerate the field and expedite the 
translation of gene-editing treatments into meaningful clinical 
applications.63 On September 13, 2018, the NIH launched a new 
initiative to help speed the development of cures for SCD.64 Dr. Gary 
H. Gibbons, director of NIH’s National Heart, Lung, and Blood 
Institute (“NHLBI”), stated, “Our scientific investments have 
brought us to a point where we have many tools available to correct 
or compensate for the defective gene that causes [SCD]. We are now 
ready to use these tools to speed up our quest for a cure.”65 
With advancements in gene therapy and a potential genome-
editing cure for SCD on the horizon, we are likely to witness a 
 
 57. Jean-Antoine Ribeil et al., Gene Therapy in a Patient with Sickle Cell Disease, 376 
NEW ENG. J. MED. 848, 849 (2017). 
 58. Id. at 848. 
 59. Id. at 854. 
 60. See, e.g., Canver et al., supra note 55, at 196; DeWitt et al., supra note 49, at 9. 
 61. News Release, Nat’l Insts. of Health, NIH to Launch Genome Editing Research 
Program (Jan. 23, 2018), https://www.nih.gov/news-events/news-releases/nih-launch-
genome-editing-research-program [https://perma.cc/HV63-GWXD]. 
 62. Francis Collins, Accelerating Cures in the Genomic Age: The Sickle Cell Example, 
NIH: DIRECTOR’S BLOG (Dec. 11, 2018), https://directorsblog.nih.gov/2018/12/11/
accelerating-cures-in-the-genomic-age-the-sickle-cell-example/ [https://perma.cc/T8TE-58YH]. 
 63. Id. 
 64. News Release, Nat’l Insts. of Health, NIH Launches Initiative to Accelerate 
Genetic Therapies to Cure Sickle Cell Disease (Sept. 13, 2018), https://www.nih.gov/news-
events/news-releases/nih-launches-initiative-accelerate-genetic-therapies-cure-sickle-cell-
disease [https://perma.cc/564H-YYJ9]. 
 65. Id. 
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watershed moment for those living with this debilitating illness, 
especially in light of SCD’s long history of neglect.66 Though the 
disease was first described over a century ago,67 very little progress 
has been made to advance affordable, accessible treatment for those 
affected by SCD.68 
Persaud, Bonham, and colleagues conducted a qualitative study 
between April and December 2017 to engage the SCD community 
and ascertain its views on gene-editing therapies.69 The study70 
consisted of fifteen focus groups: six patient, six parent, and three 
physician groups. Participants answered survey questions about their 
views on gene editing and participation in future clinical trials. 
The study examined the views of patients, parents, and 
physicians within the SCD community and found that, broadly, all 
three stakeholder groups expressed enthusiasm over a seemingly 
overdue treatment that carries the potential to completely eradicate 
SCD. One patient stated, “With me sitting here in pain right now .	.	. 
if there’s something that can be done to heal that, then I’m for it.” 
Another said, “I’m very optimistic. It’s another possible option for 
sickle cell patients and unfortunately we don’t have many.” Despite 
the community’s overall optimism, a number of reservations 
regarding gene editing were reported, especially relating to equitable 
access. “To have the sickle cell population move this forward and 
then not have this available for them equally, would be extremely 
traumatic to the community,” said one physician, especially when 
examining the SCD community’s history of discrimination.  
III.  SCD AND SCT: A LEGACY OF DISCRIMINATION 
The legacy of discrimination against the SCD community 
provides a backdrop for understanding current attitudes and 
apprehensions regarding inequitable access to a potential cure. After 
providing some general thoughts on the value-harm tradeoff inherent 
in knowing one’s sickle cell status, this part provides an overview of 
the history of discrimination against those living with SCD and SCT 
 
 66. Collins, supra note 62. 
 67. Herrick, supra note 2, at 179 & cmt. a. 
 68. Keith Wailoo, Sickle Cell Disease – A History of Progress and Peril, 376 NEW 
ENG. J. MED. 805, 805 (2017). 
 69. Anitra Persaud et al., A CRISPR Focus on Attitudes and Beliefs Towards Somatic 
Genome Editing from Stakeholders Within the Sickle Cell Disease Community, GENETICS 
MED. 1 (Dec. 24, 2019), https://www.nature.com/articles/s41436-018-0409-6.pdf [https://perma.cc/
BZ2M-HRW2]. 
 70. For the remainder of this section, the study discussed is referring to the Persaud 
and Bonham study.  
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and spotlights three especially striking examples of that 
discrimination: in the U.S. military, the workplace, and the provision 
of medical care. It then considers how the potential for discrimination 
continues.  
A. The Clinical Benefit and Harm in Knowing One’s Sickle Cell 
Carrier Status 
SCT, the heterozygous inheritance for sickle hemoglobin,71 has 
evolutionarily persisted throughout the world due to its protection 
against severe malaria syndromes.72 “In the United States, between 
2.5 to 3 million people live with SCT including an estimated 6% to 
9% of the African American population and 0.01% to 0.07% of the 
remaining population, primarily those of Arab, Southeast Asian, 
Hispanic, and Mediterranean descent.”73 SCT affects an estimated 300 
million individuals worldwide, “with a prevalence ranging from 2% to 
30% in more than 40 countries.”74 Because of its prevalence, SCT 
reproductive counseling has been identified as an important public 
health campaign and testing has been suggested in various settings.75 
SCT carriers can have children who are homozygous SCD, compound 
heterozygous SCT, or not affected at all.76 Although SCT is generally 
an asymptomatic carrier state and most individuals never have 
complications, studies have reported potential clinical manifestations 
of SCT.77 
There are instances where screening and knowledge of one’s 
SCT status are important for reproductive decisions and can help one 
to take potentially life-saving measures, e.g., preventing dehydration 
and overexertion in circumstances involving extremely challenging 
 
 71. Jelili Ojodu et al., Incidence of Sickle Cell Trait—United States, 2010, 63 
MORBIDITY & MORTALITY WKLY. REP. 1155, 1155 (2014).  
 72. Steve M. Taylor, Christian M. Parobek & Rick M. Fairhurst, 
Haemoglobinopathies and the Clinical Epidemiology of Malaria: A Systematic Review and 
Meta-Analysis, 12 LANCET INFECTIOUS DISEASES 457, 457 (2012) (“Haemoglobin AS, 
CC, and AC genotypes and homozygous and heterozygous α-thalassaemia provide 
significant protection from severe malaria syndromes .	.	.	.”).  
 73. Rakhi P. Naik et al., Clinical Outcomes Associated with Sickle Cell Trait, 169 
ANNALS INTERNAL MED. 619, 619 (2018). 
 74. Id. 
 75. REG’L OFFICE FOR AFR., WORLD HEALTH ORG., SICKLE-CELL DISEASE: A 
STRATEGY FOR THE WHO AFRICAN REGION 1 (2010), https://apps.who.int/iris/bitstream/
10665/1682/1/AFR-RC60-8.pdf [https://perma.cc/KF5L-YAMQ]; see also Althea M. Grant 
et al., Public Health Implications of Sickle Cell Trait: A Report of the CDC Meeting, 41 
AM. J. PREVENTATIVE MED. S435, S438 (2011). 
 76. REG’L OFFICE FOR AFR., WORLD HEALTH ORG., supra note 75, at 1. 
 77. Chika Duru, Out for Blood: Employment Discrimination, Sickle Cell Trait, and the 
NFL, 9 HASTINGS RACE & POVERTY L.J. 265, 269–72 (2012). 
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physical activity.78 In a controversial decision, the National Collegiate 
Athletic Association (“NCAA”) decided in 2010 that Division I 
student-athletes must be screened for SCT after a number of college 
football players with SCT died, resulting in lawsuits against the 
NCAA and the student-athletes’ universities.79 NCAA-mandated 
testing was extended to Division II schools in 2012 and Division III 
schools in the 2014–2015 academic year.80 A team of hematologists 
and experts in SCD conducted a systematic review of the literature 
from 1970 to 2018, finding only moderate evidence of risk of 
exertional rhabdomyolysis81 in those with SCT in high-exertional 
exercise settings but no sufficient evidence supporting the risk of 
 
 78. Vence L. Bonham, George J. Dover & Lawrence C. Brody, Screening Student 
Athletes for Sickle Cell Trait — A Social and Clinical Experiment, 363 NEW ENG. J. MED. 
997, 998 (2010).  
 79. Id. at 997. See generally Verdict and Settlement Summary, Lloyd v. William March 
Rice Univ., No. C-2008-56506, 2009 WL 2462617 (Tex. Dist. Ct. June 29, 2009) (detailing 
the settlement reached between parents of a deceased nineteen-year-old football player, 
the university, and the NCAA after the player experienced a fatal acute exertional 
rhabdomyolysis event associated with his SCT). In the Lloyd settlement, the NCAA 
agreed to recommend SCT testing during all routine mandatory physicals for student-
athletes at Division I institutions. Id.; Heather R. Quick, Note, Privacy for Safety: The 
NCAA Sickle-Cell Trait Testing Policy and the Potential for Future Discrimination, 97 
IOWA L. REV. 665, 667 (2012). 
A Pennsylvania appellate court noted that failing to test athletes can create a 
significant risk. See Hill v. Slippery Rock Univ., 138 A.3d 673, 680 (Pa. Super. Ct. 2016). 
The Hill court considered a negligence claim brought by a deceased student-athlete’s 
parents. Id. The parents in Hill claimed that “the university should have tested for SCT 
before allowing students to join in athletics and that the NCAA’s failure to require 
Division II schools to screen for SCT was negligent.” Id.; Matt Fair, Pa. Justices Snub 
Appeal Over NCAA’s Place in Death Suit, LAW360.COM, https://www.law360.com/
articles/877516/pa-justices-snub-appeal-over-ncaa-s-place-in-death-suit [https://perma.cc/
RQY7-SWDB (dark archive)]. The Hill court held that an increased risk of harm 
significant enough to support a negligence action can occur through a failure to act or a 
“sin of omission,” and thus the	parents sufficiently pleaded a negligence claim when they 
alleged that the NCAA’s failure to test a student for SCT increased the risk of harm to 
that student. Hill, 138 A.3d at 680. The Supreme Court of Pennsylvania denied the 
NCAA’s Petition for Allowance of Appeal. Hill v. Slippery Rock Univ., 640 Pa. 598 
(2017). 
 80. Susan L. Smith & Miriam Shuchman, Sickle Cell Screening of College Athletes: 
Legal Obligations Fulfilled, Moral Obligations Lacking, 92 OR. L. REV. 1127, 1128 (2014). 
Smith and Shuchman note that the American Society of Hematology does not support the 
mandatory testing. Id. (citing Statement on Screening for Sickle Cell Trait and Athletic 
Participation, AM. SOC’Y HEMATOLOGY (Jan. 26, 2012), https://www.hematology.org/
news/2012/7703.aspx [https://perma.cc/2NS4-U4NV]). 
 81. “Exertional rhabdomyolysis, a syndrome characterized by skeletal muscle 
degeneration and muscle enzyme leakage, has been shown to occur in normal, healthy 
individuals following strenuous exercise. In severe cases, this syndrome can result in renal 
failure and sudden death.” Gary L. Harrelson, A. Louise Fincher & James B. Robinson, 
Acute Exertional Rhabdomyolysis and Its Relationship to Sickle Cell Trait, 30 J. ATHLETIC 
TRAINING 309, 309 (1995). 
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sudden death.82 There is a continuing debate regarding the clinical 
utility of testing student-athletes to prevent risk of clinical 
complications.83 
While testing and knowledge may be quite helpful to some with 
SCT, both SCD and SCT have a long and complicated history with 
health-care delivery and the law. A legacy of discrimination, a lack of 
health-care resources, and a lack of research support are all a part of 
the history of this disease. This past may impact the sickle cell 
community’s willingness to embrace new advances in addressing the 
disease and offer up their own bodies for research to solidify such 
advances.  
B. Discrimination Against People Living with SCD and SCT 
Since its discovery, SCD has “emerged and reemerged at the 
intersection of a variety of medical, genetic, serological, 
anthropological, personal, and administrative discourses on 
whiteness, hybridity, tribes, and citizenship.”84 After his research 
“transform[ed SCD] into the ‘first molecular disease,’” Dr. Linus 
Pauling also astoundingly suggested a public health campaign 
whereby SCT carriers would be tattooed on their foreheads so they 
would be readily recognizable to one another “and avoid falling in 
love, thereby reducing the incidence of the disease.”85 In 1959, 
physician Lydia A. DeVilbiss advocated for “managing” SCD by 
means of mandatory premarital blood testing, as was done at the time 
for venereal diseases, implying “that both conditions fall within the 
realm of governance and must be addressed not only at the level of 
the individual sick body .	.	. but also at the level of the citizen, that is, 
through government programs and with respect to its implications for 
the society as a whole.”86  
Some scholars assert that SCT—not the actual disease, SCD—
has served historically as a pretext for state government surveillance 
of reproductive decisions of African Americans.87 For example, in the 
1960s and 1970s, some community members contended that because 
 
 82. Naik et al., supra note 73, at 624–25. 
 83. Charlotte Baker et al., Implementation of the NCAA Sickle Cell Trait Screening 
Policy: A Survey of Athletic Staff and Student-Athletes, 110 J. NAT’L MED. ASS’N 564, 565 
(2018); see also Duru, supra note 77, at 271.  
 84. MELBOURNE TAPPER, IN THE BLOOD: SICKLE CELL ANEMIA AND THE 
POLITICS OF RACE 3 (1999). 
 85. KEITH WAILOO, DYING IN THE CITY OF THE BLUES: SICKLE CELL ANEMIA AND 
THE POLITICS OF RACE AND HEALTH 228 (2001). 
 86. TAPPER, supra note 84, at 92–93. 
 87. Id. at 106. 
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medical professionals at government-sponsored genetic counseling 
programs “work[ed] at the behest of the state, [they] were committed 
more to eliminating blacks than to eradicating the disease.”88 
By the 1970s, SCT carriers were denied educational 
opportunities,89 as well as jobs with commercial airlines90 and 
chemical companies,91 and were disqualified from entrance into 
military academies.92 Carriers also faced challenges in obtaining 
insurance.93 Throughout the United States, states enacted laws that 
invaded the privacy of African Americans by mandating sickle cell 
testing in a paternalistic and intrusive manner. In 1971, the 
Massachusetts state legislature enacted a law that required blood tests 
for both SCT and SCD before a child could attend school.94 Even 
more invasive, the California legislature passed a law in 1971 
permitting the state’s Public Health Department to require testing of 
black citizens “whenever appropriate.”95 Instead of promoting 
education and research for treatments, the laws passed brought 
 
 88. ALONDRA NELSON, BODY AND SOUL: THE BLACK PANTHER PARTY AND THE 
FIGHT AGAINST MEDICAL DISCRIMINATION 133 (2011). 
 89. See, e.g., id. at 136 (describing the experience of a woman with sickle cell anemia 
who was denied admission to a nursing program after administrators learned of her 
medical condition). 
 90. TROY DUSTER, BACKDOOR TO EUGENICS 28 (2d ed. 2003) (“[A]lmost all of the 
major airlines grounded or fired their employees with sickle-cell trait in the early and mid-
1970s.”). As of 2014, “the Federal Aviation Administration (FAA) does not require 
screening for SCT, nor is SCT disqualifying for any class of FAA certificate.” Bryant J. 
Webber & Catherine T. Witkop, Commentary, Screening for Sickle-Cell Trait at Accession 
to the United States Military, 179 MIL. MED. 1184, 1186 (2014). Additionally, in the 2008 
clinical practice guideline, the Aerospace Medical Association did not recommend a 
universal screening for SCT for aviators. AM. SOC’Y OF AEROSPACE MED. SPECIALISTS, 
CLINICAL PRACTICE GUIDELINE FOR SICKLE CELL DISEASE/TRAIT (2008), 
http://www.asams.org/guidelines/Completed/NEW%20Sickle%20cell%20anemia.htm 
[https://perma.cc/5MGE-RJJ4]. 
 91. In 1980, the DuPont Company admitted to “routinely” conducting 
preemployment blood screening of black candidates to determine SCT carrier status. 
Richard Severo, Air Academy to Drop Its Ban on Applicants with Sickle-Cell Gene, N.Y. 
TIMES (Feb. 4, 1981), https://www.nytimes.com/1981/02/04/us/air-academy-to-drop-its-ban-
on-applicants-with-sickle-cell-gene.html [https://perma.cc/G2UM-M2JL]. While no data 
showed that carriers were at special risk in the chemical workplace, DuPont maintained 
that its screening was a service to employees, not a means for barring them from working. 
Id. 
 92. TAPPER, supra note 84, at 121–22. 
 93. See Severo, supra note 91. In a report commissioned by the National Academy of 
Sciences, the Committee for the Study of Inborn Errors of Metabolism stated “that 
although [SCT] carriers paid more for insurance with nine out of twelve companies, their 
mortality rates did not differ from those of blacks without the trait.” Id. 
 94. DUSTER, supra note 90, at 41. 
 95. Id. at 51. A California state regulation mandated sickle cell screening of all blacks 
admitted to hospitals, regardless of reason for admission. Id. at 42. 
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“minimal health implications, capricious targeting of youthful 
carriers, and the associated stigmatization without treatment or 
counseling.”96 These laws thus provided no benefit and allowed great 
intrusion into the private lives of black Americans. 
The October 1970 Journal of the American Medical Association 
(“JAMA”) article authored by a white physician at Virginia 
Commonwealth University, Robert B. Scott, “boosted sickle cell 
anemia’s visibility” in mainstream medicine and brought national 
attention to the disease.97 The article highlighted striking disparities 
that existed in funding among genetic diseases.98 For example, data 
from 1967 showed that diseases such as cystic fibrosis and muscular 
dystrophy, found predominately in populations of European descent, 
received nonpublic volunteer funding amounting to millions of 
dollars, whereas sickle cell anemia received only $100,000, even 
though all three diseases shared similar rates of incidence.99 Further, 
at that time NIH-funded grants were reported to be less common for 
SCD than other rare genetic conditions.100 Scott’s widely read JAMA 
article is stated to have played a pivotal role in spurring politicians 
who vied to be credited with meeting the neglected health needs of 
black communities.101 In 1972, Congress passed and President Nixon 
signed into law the National Sickle Cell Anemia Control Act, the first 
major U.S. law focused on SCD.102 The law increased federal funding 
exponentially to expand SCD programs that developed research and 
educational materials relating to SCD;103 it also made receipt of 
federal funding to states contingent upon sickle cell testing being 
voluntary.104 In 1976, Congress passed a law requiring Veterans 
 
 96. Id. at 41. 
 97. NELSON, supra note 88, at 121. 
 98. Robert B. Scott, Health Care Priority and Sickle Cell Anemia, 214 JAMA 731, 731 
(1970). 
 99. NELSON, supra note 88, at 124; Scott, supra note 98, at 731. 
 100. Id. 
 101. Id. at 123–25. 
 102. National Sickle Cell Anemia Control Act, Pub. L. No. 92-294, 86 Stat. 136 (1972) 
(codified as amended in scattered sections of 29 and 42 U.S.C.). 
 103. Id. at 138.  
 104. 42 U.S.C. §	300(a) (2012). The law was enacted in response to widespread genetic 
screening in the United States, purportedly aimed at exposing “poor health care systems 
by identifying carriers of sickle cell anemia” and designed to identify individuals who 
possessed the SCT, as well as SCD. Melinda B. Kaufmann, Genetic Discrimination in the 
Workplace: An Overview of Existing Protections, 30 LOY. U. CHI. L.J. 393, 402 (1999); see 
also id. at 402 n.65 (“[T]hese programs began with the best intentions, and were supported 
by African American leaders until they realized that such measures ‘would be used to 
stereotype and disadvantage the very people they sought to help.’”).  
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Administration hospitals to maintain the confidentiality of records 
relating to sickle cell anemia.105 
In the 1970s, the African American community and 
organizations, such as the Black Panthers, embraced a complex 
agenda for genetic testing, prevention, care, and alleviation of the 
disease.106 While stakeholders affiliated with the SCD and SCT 
community had separate and sometimes divergent political 
agendas,107 alleviating human suffering appears to have been the 
common driving purpose behind efforts to bring recognition, funding, 
and progress to treatment of SCD.108 
By the 1990s, however, many SCD patients experienced barriers 
to accessing comprehensive care and pain management.109 For 
example, staff at hospital emergency rooms questioned the 
authenticity of pain associated with SCD, some arguing that providing 
pain relief for SCD community members would reward “drug-
seeking” behavior.110 This attitude enabled the narrative that those 
suffering from SCD were “a variant of the inner city drug addict 
stereotype.”111 
The year 1995 marked the first year of many where federal 
genetic discrimination legislation was introduced, and then 
languished, in Congress.112 In 2000, testifying before the Senate 
Committee on Health, Education, Labor, and Pensions, then Director 
 
 105. Veterans Omnibus Health Care Act of 1976, Pub. L. No. 94-581, §	111(a)(1), 90 
Stat. 2842, 2849 (codified as amended at 38 U.S.C. §	7332(a)(1) (2012)).  
 106. NELSON, supra note 88, at 118–19. Founded in Oakland, California, in 1966, the 
Black Panther Party’s primary mission included community service and health promotion 
within the African American community. Id. at 1, 49.  
 107. Id. at 116, 148. Nelson argues that the Nixon administration’s interest in SCD was 
“a calculated political strategy,” motivated by a desire for black American votes. Id. at 
148. Nelson also asserts that the Black Panther Party used SCD as a proxy to spotlight 
“the inequities of a profit-driven U.S. healthcare system sustained by publicly funded 
biomedical research” and as a “powerful symbol of [the Party’s] affiliation with and 
service to African American communities.” Id. at 116.  
 108. WAILOO, supra note 85, at 23 (contrasting the “compassion and awareness” the 
political campaigns of the 1970s brought with the stigmatization of the disease in 1990s 
politics); Roland B. Scott, Reflections on the Current Status of the National Sickle Cell 
Disease Program in the United States, 71 J. NAT’L MED. ASS’N 679, 679 (1979) (describing 
advances in sickle cell treatment as related to politics and pointing out that, as of the late 
1970s, the advances were already at risk as sickle cell centers were already closing down).  
 109. Vani A. Mathur et al., Multiple Levels of Suffering: Discrimination in Health-Care 
Settings Is Associated with Enhanced Laboratory Pain Sensitivity in Sickle Cell Disease, 32 
CLINICAL J. PAIN 1076, 1076–77 (2016). 
 110. WAILOO, supra note 85, at 23.  
 111. Id.  
 112. See Rep. Louise Slaughter, Essay, Genetic Information Non-Discrimination Act, 
50 HARV. J. ON LEGIS. 41, 49–55 (2013).  
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of the National Human Genome Research Institute, Francis S. 
Collins, warned of the potential for “insidious discrimination” that, 
without protections in place, would undoubtedly grow from the 
Human Genome Project’s successful decoding of 3.2 billion chemical 
letters that make up the human genome.113 The African American 
community already had suffered discrimination and neglect in matters 
relating to work, health insurance, and the provision of medical care 
on numerous bases, including SCD and SCT status.114 Community 
members had legitimate concerns that population genetic testing may 
expand discrimination.115 
In 2003, President George W. Bush signed the Sickle Cell 
Treatment Act (“SCTA”) into law as an amendment to the American 
Jobs Creation Act.116 This law expanded community-based research 
and treatment grants for SCD, including the SCD Treatment 
Demonstration Program;117 in 2009, however, authorization for the 
SCTA expired and there were no immediate laws enacted to 
reauthorize funding for programs established under the SCTA.118  
For decades there has been an ebb and flow of commitment to 
the cause of those suffering from SCD. As noted earlier, in the late 
1960s, when compared with private funding for diseases occurring at 
rates comparable to SCD but primarily affecting white 
communities—e.g., cystic fibrosis and muscular dystrophy—those 
diseases garnered greater funding than what was raised for SCD.119 
Laws and policies ostensibly intended to support research and 
treatment of those affected by SCD often encountered, and continue 
to encounter, obstruction from various fronts.120 While these actions 
 
 113. Genetic Information in the Workplace: Hearing before the S. Comm. on Health, 
Educ., Labor, & Pensions, 106th Cong. (2000) (statement of Dr. Francis S. Collins, 
Director of the National Human Genome Research Institute), 2000 WL 1115522.  
 114. See supra notes 90–93 and accompanying text. 
 115. Dorothy E. Roberts, The Nature of Blacks’ Skepticism About Genetic Testing, 27 
SETON HALL L. REV. 971, 971–72 (1997). 
 116. American Jobs Creation Act of 2004, Pub. L. No. 108-357, §	712, 118 Stat. 1418, 
1558–61 (codified as amended in scattered sections of 42 U.S.C.); see also Examining 
Legislation to Improve Public Health: Hearing Before the Subcomm. on Health of the H. 
Comm. on Energy & Commerce, 114th Cong. 32 (2016) (prepared statement of Sonja L. 
Banks, President, Sickle Cell Disease Association of America) [hereinafter Examining 
Legislation to Improve Public Health]. 
 117. American Jobs Creation Act of 2004, §	712, 118 Stat. at 1558–61. 
 118. Examining Legislation to Improve Public Health, supra note 116, at 2. 
 119. Scott, supra note 98, at 731; see also NELSON, supra note 88, at 124 (outlining the 
obvious racial implications of underfunding for SCD). 
 120. DUSTER, supra note 90, at 61–62. Over the years, other groups began demanding 
federal funding for their own diseases, while others argued successfully for a single 
comprehensive bill covering all disorders. Id. at 62.  
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may not be deliberately aimed at marginalizing the SCD community, 
the effect may be experienced as such. For example, passage of the 
Sickle Cell Disease and Other Heritable Blood Disorders Research, 
Surveillance, Prevention, and Treatment Act of 2018 highlights 
Congress’s commitment to push forward with research that will 
increase understanding of the “prevalence, distribution, outcomes, 
and treatments associated with SCD.”121 This law was originally 
drafted to exclusively focus on SCD; however, it was expanded before 
passage to include other blood disorders.122 Still, the new law is 
beneficial in that “[i]t also reauthorizes SCD prevention and 
treatment grants awarded by the Health Resources and Service 
Administration (HRSA), and it authorizes the Centers for Disease 
Control and Prevention [(‘CDC’)] to award SCD surveillance grants 
to states, academic institutions and nonprofit organizations.”123	 
Though progress has been made at the federal level, some state 
laws specifically applicable to SCD remain on the books, and some of 
these laws invade genetic privacy rights of patients and the parents of 
those patients who have SCD or SCT.124 In other instances, laws not 
 
 121. The President Signs the Sickle Cell Treatment Act of 2018!, SICKLE CELL DISEASE 
ASS’N AM., INC. (Dec. 19, 2018), https://www.sicklecelldisease.org/2018/12/19/the-
president-signs-the-sickle-cell-treatment-act-of-2018/ [https://perma.cc/WV5J-NQFK]. 
 122. Compare Sickle Cell Disease Research, Surveillance, Prevention, and Treatment 
Act of 2018, S. 2465, 115th Cong. (2018) (as proposed in Senate, Feb. 28, 2018), with Sickle 
Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, 
and Treatment Act of 2018, S. 2465, 115th Cong. (2018) (proposed as an amendment in 
the nature of a substitute in Senate, Aug. 15, 2018) (amending the bill to, in effect, reduce 
the funds and available resources for SCD). The latter version was signed into law on 
December 18, 2018. The President Signs the Sickle Cell Treatment Act of 2018!, supra note 
121.  
 123.  Id. 
 124. DUSTER, supra note 90, at 62 (“While the federal law eliminated compulsion, it 
has also brought mass genetic screening into the sphere of routine public health activities. 
Given the fact that many screening laws have not actually been repealed and that 
compulsory screening programs might survive a court test, it is not frivolous to suggest 
that the current popularity of voluntary laws is no guarantee that mandatory programs will 
not someday be resumed.”). By 1987, newborn screening was again mandatory in seven 
states. Id. As of 2007, routine state screening of newborns was universal throughout the 
United States, and as of 2025, “nearly all individuals enlisting in the military should have 
been previously screened.” KENNETH LIN & MARY B. BARTON, U.S. DEP’T OF HEALTH 
& HUMAN SERVS., SCREENING FOR HEMOGLOBINOPATHIES IN NEWBORNS: 
REAFFIRMATION UPDATE FOR THE U.S. PREVENTIVE SERVICES TASK FORCE 1 (2007), 
https://www.ahrq.gov/downloads/pub/prevent/pdfser/sicklecelles.pdf [https://perma.cc/5647-
LXN9]; see also SEC’Y’S ADVISORY COMM. ON HERITABLE DISORDERS IN NEWBORNS & 
CHILDREN, U.S. DEP’T OF HEALTH & HUMAN SERVS., SCREENING U.S. COLLEGE 
ATHLETES FOR THEIR SICKLE CELL DISEASE CARRIER STATUS 11–13 (2010), 
https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/
reports-recommendations/reports/college-athletes-sickle-cell.pdf [https://perma.cc/
Z5SN-9D6B]; Webber & Witkop, supra note 90, at 1188. 
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specifically focused on genetic information still play a critical role in 
protecting individuals with manifested or diagnosed medical 
conditions such as SCD.125 As discussed later in this Article, for these 
individuals, federal protections under the Genetic Information 
Nondiscrimination Act of 2008 (“GINA”) do not cover manifested or 
diagnosed genetic diseases.126 Thus, case law specifically addressing 
the rights of those with SCD—even cases dating back to the 1980s—
can be instructive and relevant in understanding current rights under 
the law. 
C. Discrimination in the Military 
Although the 1972 National Sickle Cell Anemia Control Act 
curtailed state-ordered mandatory testing, controversial practices 
based upon disputed scientific evidence continued to inform U.S. 
military policies that discriminated against SCT carriers. Such policies 
held that recruits with SCT would be barred from submarine service 
in the U.S. Navy and from serving as air crew members in the U.S. 
Army.127 The death of four black Army recruits out of approximately 
four thousand between March 1968 and February 1969 at a moderate 
altitude (>4060) training camp led the National Academy of Sciences 
and National Research Council to request, and the U.S. Department 
of Defense (“DoD”) to organize, a committee to investigate and 
make recommendations.128 In 1970, the Military Aviation Safety 
Subcommittee determined that data on clinical outcomes associated 
with SCT carrier status were inadequate but nevertheless 
recommended screening for both the trait and disease in all recruits 
“regardless of race.”129 Additionally, the committee recommended 
limitations on SCT carriers’ military activities, such as in “aviation, 
diving, special forces [assignments] and high-altitude parachuting.”130 
However well intentioned the committee’s recommendations were, 
 
 125. For examples of discrimination in the workplace and the use of ADA and section 
504 of the Rehabilitation Act where the Genetic Information Nondiscrimination Act of 
2008 would otherwise not have provided protection against discrimination of a manifested 
genetic condition, see infra Section III.D.  
 126. See infra Section V.B.2.   
 127. Severo, supra note 91. 
 128. DUSTER, supra note 90, at 26–27; Mauricio De Castro et al., Genomic Medicine in 
the Military, 1 GENOMIC MED., no. 15008, Jan. 13, 2016, at 1, 1; V.M. Voge, N.R. Rosado 
& J.J. Contiguglia, Sickle Cell Anemia Trait in the Military Aircrew Population: A Report 
from the Military Aviation Safety Subcommittee of the Aviation Safety Committee, AsMA, 
62 AVIATION, SPACE & ENVTL. MED. 1099, 1100 (1991). 
 129. DUSTER, supra note 90, at 27; De Castro et al., supra note 128, at 2. 
 130. De Castro et al., supra note 128, at 2. 
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the investigation lacked “essential controls and comparisons.”131 
Though largely based on mere observation of frequencies—inviting 
the hazard “of spurious relations and false conclusions”132—the 
committee’s recommendations were implemented “by all branches of 
the U.S. military in 1973.”133 At the time, many scientists and 
physicians believed that restrictions relating to those carrying SCT are 
“a senseless stigma and an unscientific suggestion that their genes are 
somehow inferior.”134 
1.  U.S. Air Force Academy Prohibitions and Successful Challenge 
Following the committee’s recommendations, the U.S. Air Force 
(“USAF”) Academy adopted a policy of excluding blacks who 
carried SCT.135 This policy was applied only to the elite Air Force 
Academy—the Air Force Reserve Officers’ Training Corps 
(“ROTC”) scholarship program did “not disqualify blacks from 
general enlistment or from being commissioned.”136 
Stephen Pullens, a former state champion high hurdler and four-
sport star athlete and mountain climber, passed the Air Force 
Academy’s pilot qualifying exam, including a physical examination, 
before reporting to the school in July 1979.137 After a blood test 
revealed Pullens’s SCT carrier status, he was forced to leave the 
Academy.138 The Air Force argued that it had legitimate interests in 
screening future and current pilots for health problems.139 Sociologist 
Troy Duster contends that the Air Force’s position that SCT-carrying 
pilots would pose potential risks to others or would themselves 
experience heightened risks indicates that Pullens’s dismissal 
presented yet another instance of “appropriated genetic explanation” 
 
 131. DUSTER, supra note 90, at 27. 
 132. Id. 
 133. Voge et al., supra note 128, at 1100. 
 134. Severo, supra note 91.  
 135. DUSTER, supra note 90, at 28. 
 136. Air Force Academy Sued over Sickle Cell Policy, N.Y. TIMES (Jan. 4, 1981), 
https://www.nytimes.com/1981/01/04/us/air-force-academy-sued-over-sickle-cell-policy.html 
[https://perma.cc/9CMY-3624]. 
 137. Id. The complaint cited to then-General Air Force Regulation 60-43, 5-11, which 
stated that SCT carrier status would not disqualify an individual from entering military 
service because those with the trait show no handicapping symptoms at altitudes above 
10,000 feet or under physical stress, and rarely experience complications. Id. The 
complaint alleged that Pullens was never tested to ascertain if he could handle such 
stresses and that the Academy’s and Air Force’s regulations conflicted and denied due 
process and equal protection of the law. Id. 
 138. Id.; see also DUSTER, supra note 90, at 28. 
 139. Severo, supra note 91. 
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unsupported by research.140 In the context of numerous 
discriminatory and stigmatizing actions taken in the name of 
unproven dangers of SCT, the Air Force Academy screening policy 
appeared to be “set up only to block, not to provide the grounds for 
further empirical investigation.”141 
In 1980, with support from the NAACP, Pullens sued the U.S. 
Air Force in the U.S. District Court for the District of Minnesota.142 
By early 1981, the case was settled, and the Air Force Academy 
eliminated its ban on SCT-carrying airmen.143 A new policy made 
“[c]andidates for the Air Force Academy who [had SCT] .	.	. eligible 
for admission, provided they [were] otherwise medically qualified and 
[met] the standard entrance requirements.”144 Pullens met all of the 
requirements.145 
2.  Different Branches, Different Practices 
In 1981, all U.S. military services permitted those with SCT to be 
assigned to aviation duties with only limited restrictions.146 During 
this time, the DoD required screening of all new service members but 
only restricted the activities of those servicemen who tested as greater 
than 41% sickle hemoglobin (“HbS”).147 Under the DoD directive, 
the various branches undertook a number of different initiatives to 
gather information, monitor, study, and compile and compare data 
regarding SCT-carrying service members and control individuals.148 
By 1985, “the DoD eliminated the [>41% HbS] cutoff,” removing all 
restrictions for SCT carriers in occupational specialties.149  
Again in the 1990s, after three USAF recruit deaths, the Armed 
Forces Epidemiology Board revisited the possibility of specialty 
restrictions for SCT carriers, recommended against SCT screening, 
and instead recommended heat injury prevention.150 In 1996, the DoD 
 
 140. DUSTER, supra note 90, at 28. 
 141. Id. at 30. 
 142. Pullens v. U.S.A.F., No. 4-80 Civil 595 (D. Minn. July 21, 1981) (on file with the 
North Carolina Law Review).  
 143. Severo, supra note 91. 
 144. Id. (reporting statements made by the Air Force Surgeon General, Lieutenant 
General Paul W. Myers); see also Webber & Witkop, supra note 90, at 1185 (describing 
the DoD’s policy that dropped the occupational restrictions on SCT service members and 
also mandated SCT screening).  
 145. See Severo, supra note 91.  
 146. Voge et al., supra note 128, at 1100. 
 147. Webber & Witkop, supra note 90, at 1185. 
 148. Voge et al., supra note 128, at 1100–01. 
 149. Webber & Witkop, supra note 90, at 1185. 
 150. Id.  
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updated Instruction 6465.1 to eliminate the mandated Hemoglobin S 
testing for SCT in all military accessions.151 And yet, as of 2014, the 
Air Force, Navy, and Marine Corps continued to “screen all 
accessions for disqualifying hemoglobin disorders and mandat[ed] 
dismissal of all individuals whose HbS concentration exceed[ed] 
45%[, and although t]he Army selectively screen[ed] individuals 
entering certain military occupational specialties (e.g., aviation, 
diving, and special operations),” the Army did not “consider SCT a 
disqualifying condition.”152 Practices at service academies have 
continued to vary with no cohesive policies in place.153 
The U.S. military’s approach to addressing SCT in recruits 
clearly remains unsettled.154 A 1987 study found that SCT was 
associated with a higher risk of exercise-related sudden death.155 A 
2016 study of military recruits did not find an association between a 
higher risk of exercise-related sudden death for those with SCT as 
opposed to other recruits; it did find a significantly higher risk of 
exertional rhabdomyolysis in recruits with the trait.156 A 2018 
systematic review of the clinical literature found moderate evidence 
that in high-exertional exercise settings there is a risk of exertional 
rhabdomyolysis in those with SCT, but there is insufficient evidence 
to support a risk of sudden death.157 The study stated that prospective 
large-scale research studies to understand the clinical risk associated 
with SCT are needed.158 Today, the need persists for research to 
protect the safety of recruits with SCT and the development of 
uniform service-wide policies based on rigorous empirical studies. As 
reported in 2014,  
[t]he USAF, Navy, and Marine Corps provid[ed] group-based 
counseling for SCT+ recruits early in basic training, but 
interventions differ[ed]: USAF recruits [would] wear a white 
armband at all times throughout training; Navy recruits [would] 
wear a red belt or red dog tag during exercise; and Marine 
Corps recruits [were] not publicly identified.159  
 
 151. Id. 
 152. Id.  
 153. Id. 
 154. See De Castro et al., supra note 128, at 4. 
 155. John A. Kark et al., Sickle-Cell Trait as a Risk Factor for Sudden Death in Physical 
Training, 317 NEW ENG. J. MED. 781, 781 (1987). 
 156. D. Alan Nelson et al., Sickle Cell Trait, Rhabdomyolysis, and Mortality Among 
U.S. Army Soldiers, 375 NEW ENG. J. MED. 435, 436 (2016). 
 157. Naik et al., supra note 73, at 625. 
 158. Id. 
 159. Webber & Witkop, supra note 90, at 1185. 
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While the military has a significant interest in quickly identifying 
genetic traits of recruits for health and safety purposes,160 the 
branches should be cognizant of potential discrimination. 
D. Discrimination in the Workplace 
Employees affected by discrimination or stigma based on actual 
or perceived sickle cell status have attempted to assert their legal 
rights. A few standout sickle cell cases have helped to raise awareness 
of discriminatory practices and have been elevated to the national 
stage for use in informing and shaping federal law and policy. 
A seminal genetic discrimination case, Norman-Bloodsaw v. 
Lawrence Berkeley Laboratory,161 considered whether an employee 
“may, without [his/her] knowledge [or consent], be tested for highly 
private and sensitive medical and genetic information,” such as SCT, 
during a general employee physical.162 This case is frequently cited in 
genetic discrimination literature and was specifically referenced in the 
“Findings” section of GINA.163 As the first class action case alleging 
discrimination and invasion of privacy in relation to genetic testing in 
the workplace, Norman-Bloodsaw represents the reality of everyday 
genetic discrimination in the workplace before passage of GINA, the 
federal legislation intended to protect employees.164 The case is still 
influential in circumstances where genetics protections under federal 
and state law are lacking.165 
In Norman-Bloodsaw, the employer was a federal contractor 
with the U.S. Department of Energy, and the named defendants were 
sued in both their official and individual capacities.166 All but one of 
 
 160. “The military has a legitimate interest in obtaining information about warfighters’ 
physical and mental abilities, including genomic information, but only if the genomic test 
is a valid indicator of what it purports to show and the information is necessary in order to 
carry out the mission.” De Castro et al., supra note 128, at 3. 
 161. 135 F.3d 1260 (9th Cir. 1998). 
 162. Id. at 1264. 
 163. 42 U.S.C. §	2000ff cmt. 4 (2012) (Legislative Findings) (“Congress has been 
informed of examples of genetic discrimination in the workplace. These include the use of 
pre-employment genetic screening at Lawrence Berkeley Laboratory, which led to a court 
decision in favor of the employees in that case[.] Norman-Bloodsaw v. Lawrence Berkeley 
Laboratory (135 F.3d 1260, 1269 (9th Cir. 1998)). Congress clearly has a compelling public 
interest in relieving the fear of discrimination and in prohibiting its actual practice in 
employment and health insurance.”).  
 164. Elizabeth Pendo, Race, Sex, and Genes at Work: Uncovering the Lessons of 
Norman-Bloodsaw, 10 HOUS. J. HEALTH L. & POL’Y 227, 230 (2010). 
 165. Id. at 229 (“[G]enetic testing of workers occurs and is likely to continue even after 
GINA, and the gathering and use of genetic information in the workplace is not neutral 
and often exacerbates long-standing patterns of discrimination based on race and sex.”). 
 166. Norman-Bloodsaw, 135 F.3d at 1264. 
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the plaintiffs were individuals who had “received written offers of 
employment expressly conditioned upon a ‘medical examination,’ 
‘medical approval,’ or ‘health evaluation.’”167 In the process of 
completing medical history questionnaires and providing blood and 
urine samples, the plaintiffs were asked if they had any of sixty-one 
medical conditions, including sickle cell anemia.168 Thereafter, blood 
samples were tested for SCT, without notice or consent, and allegedly 
this testing was only conducted on samples from black employees.169 
In 1995 the plaintiffs obtained an Equal Employment 
Opportunity Commission (“EEOC”) right-to-sue letter on behalf of 
both past and present employees who were at any time subjected to 
the testing at issue.170 Specifically, the plaintiffs alleged that the 
defendants violated: (1) the Americans with Disabilities Act of 1990 
(“ADA”) by “requiring, encouraging, or assisting in medical testing 
that was neither job-related nor consistent with business necessity”; 
(2) the constitutional right to privacy under both federal and 
California law; and (3) “Title VII by singling out black employees for 
[SCT] testing.”171 After the district court dismissed all claims, the 
plaintiffs filed an appeal in the Ninth Circuit.172 Ultimately, the 
appellate court affirmed the dismissal of the ADA claims but 
reversed on the Title VII and the federal and state privacy claims 
under the U.S. and California Constitutions.173 
With regard to SCT, the appellate court stated that carrier status 
pertains to “sensitive information about family history and 
reproductive decision making,” and these were “aspects of one’s 
health in which one enjoys the highest expectations of privacy.”174 The 
appellate court further found that the alleged discrimination fell 
“neatly into a Title VII framework,” namely that the plaintiffs had 
alleged “that black .	.	. employees were singled out for additional 
nonconsensual testing and that defendants thus selectively invaded 
 
 167. Id. at 1264–65. The employer represented that the program’s objectives were “to 
protect employees from possible health hazards in their work environment; to assure 
placement in work that can be performed in a reliable and safe manner; to promote early 
detection, treatment and rehabilitation; and to apply preventative medical measures 
toward the maintenance of good physical and mental health .	.	.	.” Pendo, supra note 164, 
at 232 (quoting Brief of Defendants–Appellees, Norman–Bloodsaw v. Lawrence Berkeley 
Lab., 135 F.3d 1260 (9th Cir. 1998) (No. 96-16526), 1997 WL 33633545, at *9–10). 
 168. Norman-Bloodsaw, 135 F.3d at 1265. 
 169. Id. 
 170. Id. 
 171. Norman-Bloodsaw, 135 F.3d at 1265–66. 
 172. Id. at 1266. 
 173. Id. at 1275. 
 174. Id. at 1270. 
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the privacy of certain employees on the basis of race.”175 Although the 
district court held that the tests were not a condition of employment, 
the Ninth Circuit found that, since “the preplacement exams were, 
literally, a condition of employment,” the fact that the preplacement 
exam tested black employees for SCT made it a condition of 
employment.176 
The parties reached a settlement in this case under which 
Lawrence Laboratories paid $2.2 million to the plaintiffs.177 Further, 
Lawrence Laboratories agreed to implement new procedures that 
would prohibit employee testing without informed consent and 
provide employees opportunities to review their medical records.178 
Lawrence Laboratories also offered to expunge from the medical 
records any testing information—positive or negative—relating to 
SCT.179 
Additionally, in Fleming v. State University of New York,180 a 
plaintiff’s SCD became the center of employment litigation involving 
an aspiring young doctor. Dr. Lester Fleming, an anesthesiologist, had 
recently completed his residency at the State University of New York 
(“SUNY”) and was seeking permanent employment at the Yuma 
Regional Medical Center in Arizona (“Yuma”).181 After Yuma and 
Dr. Fleming entered into an employment contract, Yuma began a 
credentialing process that included inquiries with Dr. Fleming’s 
former employers.182 During this process, the SUNY residency 
program director disclosed Dr. Fleming’s SCD to Yuma.183 After 
confirming this diagnosis with Dr. Fleming’s hematologist, Yuma 
informed Dr. Fleming that he should seek employment elsewhere.184 
Yuma modified Dr. Fleming’s employment offer, adding the 
requirement that he sign an acknowledgement stating that, if he were 
to fall ill, Yuma was not able to provide him a reasonable 
accommodation for his operating room and call schedules.185 Dr. 
 
 175. Id. at 1272. 
 176. Id. 
 177. Pendo, supra note 164, at 246. 
 178. Id. 
 179. Id. 
 180. 502 F. Supp. 2d 324 (E.D.N.Y. 2007). 
 181. Id. at 327. 
 182. Id. 
 183. Id. 
 184. Id. 
 185. Id. 
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Fleming refused to sign the contract addendum and characterized the 
added requirement as constructive termination in his lawsuit.186 
The district court found merit in Dr. Fleming’s claim under 
section 504(d) of the Rehabilitation Act because section 504 adopts 
the ADA’s Title I provision that declares: “No covered entity shall 
discriminate against a qualified individual with a disability because of 
the disability of such individual in regard to job application 
procedures, the hiring, advancement, or discharge of employees, 
employee compensation, job training, and other terms, conditions, 
and privileges of employment.”187 The defendants—Dr. Fleming’s 
former employers—had described Dr. Fleming as a person suffering 
from sickle cell anemia, thus classifying him as a person with a 
disability; this classification, in turn, adversely affected his 
opportunities to work as an anesthesiologist.188 
Further, citing Second Circuit precedent, the district court 
asserted that an individual’s constitutional right to privacy in his 
health status protects information about “‘serious medical 
condition[s],’ especially those that are likely to provoke .	.	. 
‘discrimination and intolerance.’”189 Finding that sickle cell anemia is 
such a disease with “the potential to provoke intolerance and 
discrimination,” the court rejected SUNY’s contention that sickle cell 
anemia “falls far short of the ‘excruciatingly private and intimate’ 
medical conditions that inevitably provoke ‘hostility and intolerance 
from others.’”190 The court noted that, while there are few reported 
cases of discrimination based on sickle cell anemia, “a history of such 
discrimination exists”191 and found that Dr. Fleming’s Fourteenth 
Amendment right to privacy in health information did, indeed, entitle 
him to confidentiality regarding his sickle cell anemia.192 
Two years later, Dr. Fleming was before the Ninth Circuit in his 
lawsuit against Yuma.193 There, and in the underlying case, he alleged 
 
 186. Id. 
 187. Id. at 336. 
 188. Id. at 337. 
 189. Id. at 342 (first alteration in original) (quoting Doe v. City of New York, 15 F.3d 
264, 267 (2d Cir. 1994)). While Doe involved the confidentiality of HIV status, the Fleming 
court stated: “The holding of Doe thus plainly applies to [SCD], which, while arguably 
less likely than HIV to provoke discrimination and intolerance, nonetheless may do so, 
and indeed has done so in the past.” Id. at 345. The Fleming court also noted that malice 
or bad intent in the disclosure of such private information was not a prerequisite to 
establishing an actionable claim. Id. 
 190. Id.  
 191. Id. at 343. 
 192. Id. 
 193. Fleming v. Yuma Reg’l Med. Ctr., 587 F.3d 938 (9th Cir. 2009). 
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that Yuma’s refusal to accommodate his operating and call schedules 
due to his sickle cell anemia constituted a breach of employment 
contract and disability discrimination in violation of the 
Rehabilitation Act of 1973.194 The district court had granted Yuma’s 
motion for summary judgment, finding that the Rehabilitation Act 
was inapplicable.195 The Ninth Circuit reversed,196 and the Supreme 
Court denied Yuma’s petition for writ of certiorari.197 
E. Discrimination in Provision of Medical Care 
Avery v. County of Burke198 is an important example of how 
status as a sickle cell carrier has been used to justify extreme, 
unnecessary, and ill-informed decisionmaking in the provision of 
medical care. In this case, the Fourth Circuit vacated the lower court’s 
entry of summary judgment against a fifteen-year-old woman, 
Virginia Ann Avery, who was told by state employees that she had 
SCT and was then advised to undergo a sterilization procedure.199 The 
state clinic’s nurses and doctor “told Avery and her mother that 
because Avery had [SCT], childbirth would either immediately 
endanger her life” or shorten it by “two or three years,”200 and that 
pregnant women with SCT are more “susceptible to numerous 
diseases.”201 Based on these representations, Virginia Avery and her 
 
 194. Id. at 940. Section 504(a) of the Rehabilitation Act of 1973 creates a private right 
of action for individuals subjected to disability discrimination by any program or activity 
receiving federal financial assistance. 29 U.S.C. §	794a(a)(2) (2012). 
 195. See Fleming, 587 F.3d at 940. Yuma had argued that it was not subject to 
requirements of the Rehabilitation Act because the anesthesiologist position at issue was 
that of an independent contractor. See id.  
 196. See id. at 939 (holding that section 504 of “the Rehabilitation Act [does in fact] 
cover[] discrimination claims by an independent contractor”). Furthermore, the Ninth 
Circuit found “[t]he Rehabilitation Act covers any ‘otherwise qualified individual’ who 
has been ‘excluded from the participation in, or denied the benefits of, or .	.	. subjected to 
discrimination under any program or activity receiving Federal financial assistance.’” Id. at 
941–42 (second alteration in original) (quoting 29 U.S.C. §	794(a) (2012)). Thus, the Act 
“covers ‘all of the operations’ of covered entities, not only those related to employment.” 
Id. at 942 (quoting 29 U.S.C. §	794(b) (2012)).  
 197. Fleming v. Yuma Reg’l Med. Ctr., 561 U.S. 1006 (2010). As of 2019, Doctor 
Fleming is a successful anesthesiologist practicing in the state of Virginia. Dr. Lester 
Fleming, U.S. NEWS & WORLD REP., https://health.usnews.com/doctors/lester-fleming-
191363 [https://perma.cc/H298-8QU9 (staff-uploaded archive)]. 
 198. 660 F.2d 111 (4th Cir. 1981). 
 199. Id. at 113. 
 200. Id. The Fourth Circuit observed that SCT “is the carrier gene state of sickle cell 
syndrome which exclusively affects black people.” Id. (emphasis added). Additionally, 
both nurses involved in “Avery’s sterilization testified that they had no special training in 
handling sickle cell cases.” Id. at 115.  
 201. Id. at 113. 
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mother consented to sterilization and a North Carolina state court 
authorized the procedure.202 Subsequent to her sterilization,203 Avery 
underwent additional testing that showed she did not have SCT.204 
This case represents an example of paternalism, fear tactics, and 
possibly deliberate malfeasance in order to control a black woman’s 
reproductive choices. 
Under 42 U.S.C. §	1983, Avery brought suit against the County 
Board of Health and County Board of Social Services, alleging 
violations of her Fourteenth Amendment rights of privacy and 
procreation.205 She argued that “she was wrongfully sterilized because 
she did not have [SCT] and because sterilization is not medically 
recommended or proper, even when there has been a correct 
diagnosis of the trait.”206 After having been pressured into submitting 
to the sterilization procedure so she could not bear children, Avery’s 
claims were dismissed by the U.S. District Court for the Western 
District of North Carolina.207 The Fourth Circuit Court of Appeals 
revived the case, stating, “It is not essential .	.	. [to] show that all 
persons suspected of having [SCT] have been mistreated [by the 
county]. It is enough that an identifiable group of people .	.	. is subject 
to constitutional deprivations through the inaction of the boards.”208 
The Avery case is just one more example of the legacy of 
discrimination against those in the SCD and SCT community, as well 
as those perceived as belonging to that community. 
IV.  COMMUNITY ENGAGEMENT IS VITAL IN PREVENTING 
PERPETUAL HEALTH INEQUITIES 
While SCT and SCD community members remain optimistic, the 
legacy of discrimination informs and heightens their uneasiness and 
apprehension about inequitable access to curative genetic treatments 
that the community, by participating in human genome-editing 
technology research, will have brought to fruition. As seen in the 
 
 202. Id. 
 203. Id. at 112.  
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 208. Id. at 114 (citing Withers v. Levine, 615 F.2d 158, 161 (4th Cir. 1980), abrogated by 
Moore v. Winebrenner, 927 F.2d 1312 (4th Cir. 1991)) (“North Carolina law required both 
[the health and social services] boards to supervise their employees and to promulgate 
guidelines and policies to protect the health and well-being of the citizens of the county.”). 
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Persaud-Bonham study,209 members of the SCD community, their 
families, and their physicians have voiced a concern that the SCD 
community may participate in the clinical trials and then not benefit 
equitably from advances in gene-editing technology.210 The National 
Academies of Sciences, Engineering, and Medicine 2017 Report on 
Human Genome Editing concluded that “extensive and inclusive 
public participation should precede clinical trials for any extension of 
human genome editing beyond treatment or prevention of disease or 
disability.”211 The report further stated that “[p]ublic participation 
should be incorporated into policy-making process[es] for human 
genome editing and should include ongoing monitoring of public 
attitudes, informational deficits, and emerging concerns about issues 
surrounding ‘enhancement.’”212 This Article contends that public 
engagement and opinions are required not just for use of genome 
editing for enhancement and germline alterations but for treatment to 
prevent or cure disease and lessen disabling consequences of disease. 
Due in part to the uncertainty related to the long-term impact of 
gene editing, and the legacy of discrimination experienced by the 
SCD community, participants in the Persaud-Bonham study 
emphasized the need for absolute transparency by government and 
biomedical researchers with respect to the development of clinical 
trials. Study participants all wanted the government and researchers 
to respect the community’s views and to meaningfully engage the 
community in the development of clinical trials. A patient in the study 
articulated this point, stating: “We need a seat at the table. When this 
clinical trial is going on and you’ve got the researchers setting up 
protocols, setting up how it is going to work—advocacy, [Community 
Based Organization] .	.	. people that have sickle cell, need to be 
involved in every aspect of the trial.”  
In some respects, the study participants provided strategies for 
how these goals could be met, including (1) partnerships with brokers 
of trust within the community, (2) development of clear and effective 
educational tools, (3) dissemination of information relevant to the 
prospective participants through social media and other commonly 
used communication platforms, and (4) a commitment to dedicating 
resources to advance the treatment and care of SCD patients 
 
 209. Persaud et al., supra note 69, at 7. In this section, further discussion of “the study” 
also refers to the Persaud-Bonham study. See supra Section II.C. 
 210. See supra Section II.C. 
 211. See NAT’L ACADS. OF SCIS., ENG’G, & MED., supra note 5, at 178 (emphasis 
added).  
 212. Id. 
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regardless of whether the fruits of gene editing come to bear. 
Physicians, on the other hand, stressed being clear about the 
limitations of gene editing, avoiding both explicit and implicit 
coercion, and walking the path carefully to prevent further alienation 
of the community. One physician offered the following comments:  
I would say don’t mess it up .	.	. if you are really talking about it 
impacting the sickle cell population, you have to be very careful 
that the other rare diseases that have more resources don’t take 
it over and the sickle cell population gets left in the dust. [Sickle 
cell patients] have been left in the dust with so many other 
things that they already are skeptics.  
All three stakeholders—patients, parents, and physicians—were 
concerned that access to gene-editing treatments in the future would 
comprise a huge impediment to care and warned against using the 
community as a means to an end. 
Systematic public engagement of the disease communities in 
developing gene-editing clinical trials and public education resources 
is necessary. This engagement should not be limited to the most 
controversial uses of the new technology, e.g., germline gene editing 
or genetic enhancement; it is equally essential for uses related to 
somatic gene editing for treatment and prevention of disease. The 
equitable access to curative genetic therapies—like gene therapy and 
gene editing—requires public input to guide public policy. Especially 
when the disease—like SCD—is surrounded by a history of abuse and 
neglect. 
V.  LEGAL PROTECTIONS OF INDIVIDUALS’ GENETIC INFORMATION 
Though the SCD and SCT community has experienced ongoing 
discrimination, Congress has endeavored to create meaningful 
protections. This section considers GINA and the protections, and 
lack thereof, which it provides to the historically undermined and 
marginalized SCD and SCT community. Prior to GINA’s enactment, 
there were up to 500 documented cases of genetic discrimination in 
the United States.213 Without a law specifically guarding against this 
discrimination, laws such as Title VII of the Civil Rights Act of 
1964,214 the Americans with Disabilities Act of 1990,215 section 504 of 
 
 213. Ifeoma Ajunwa, Genetic Data and Civil Rights, 51 HARV. C.R.-C.L. L. REV. 75, 
77–78 (2016). 
 214. With all the protections Title VII affords, this law makes no mention of genetic 
information or health information. See Slaughter, supra note 112, at 47.  
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the Rehabilitation Act of 1973, and the Health Insurance Portability 
and Accountability Act of 1996 (“HIPAA”)216 sometimes provided 
recourse and remedies for those suffering from discrimination based 
on genetic information or disease. However, when these earlier 
federal employment, antidiscrimination, and health-care privacy laws 
were enacted, the potential for genetic knowledge and the 
discriminatory implications and ramifications of genetic testing could 
 
 215. Carriers of genetic mutations who do not have or exhibit a symptomatic disorder 
are not explicitly covered by the ADA. Slaughter, supra note 112, at 47–48. A 1995 
Guidance issued by EEOC advised employers to refrain from taking action against 
otherwise healthy employees and applicants based on the presence of genetic mutations 
that may have predisposed the employee or applicant to disease. Id. at 48. But guidance is 
just that—guidance, not law. See id. Still, guidelines do “constitute a body of experience 
and informed judgment to which courts and litigants may properly resort for guidance.” 
Skidmore v. Swift & Co., 323 U.S. 134, 140 (1944). 
Unlike Title VII and the ADA, GINA lacks a disparate impact liability provision. See 
42 U.S.C. §	2000ff-7(a)–(b) (2012) (recognizing that allegations of disparate impact on the 
basis of genetic information does not establish cause of action under GINA); 29 C.F.R. 
§	1635.5(b) (2018); Ajunwa, supra note 213, at 84. However, this could change because, 
though GINA was not intended to address specific protected classes, under 42 U.S.C. 
§	2000ff-7(b), GINA requires that  
[o]n the date that is 6 years after May 21, 2008, there shall be established a 
commission, to be known as the Genetic Nondiscrimination Study Commission 
(referred to in this section as the “Commission”) to review the developing science 
of genetics and to make recommendations to Congress regarding whether to 
provide a disparate impact cause of action under this Act. 
§	2000ff-7(b). This should have occurred in May 2014, but it still has not. Ajunwa, supra 
note 213, at 86–87, 87 n.74. Ajunwa suggests that the increased protection afforded by 
disparate impact theory is needed to extend GINA’s reach where a plaintiff is unable to 
obtain “actual evidence of genetic discrimination.” Id. at 105. Ajunwa offers the following 
four reasons that support addition of a disparate impact clause to GINA:  
(1) [the] theory .	.	. is in line with the precedent set by prior employment 
discrimination laws; (2) the EEOC has declared that proof of deliberate 
acquisition of genetic information is not necessary to establish a violation of 
GINA, and proof of intent to discriminate likewise should not be required to 
demonstrate genetic discrimination; (3) ease of access to genetic testing and the 
insecurity of genetic information has increased the likelihood of genetic 
discrimination in employment; and (4) real world instances of genetic testing have 
shown that facially neutral testing may result in racial disparities. 
Id. at 100. 
 216. HIPAA prohibits health insurance companies from assessing higher premiums for 
unwell individuals within an employer-sponsored group policy, or from excluding 
preexisting conditions; however, the group as a whole can be charged higher premiums. 
See Slaughter, supra note 112, at 48. Therefore, there is a disincentive for employers to 
hire potential employees who might be perceived as more likely to need medical care 
and/or to be carrying genetic mutations. See Ajunwa, supra note 213, at 89. This 
disincentive may work against women of childbearing age, older workers, and those who 
fit race-based assumptions about health conditions such as SCT and SCD. 
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not be fully envisioned.217 GINA’s drafters incorporated instructions 
to close certain gaps in protections.218 For example, as required by 
GINA, 2013 revisions to the HIPAA Privacy Rule added that genetic 
information is Protected Health Information (“PHI”) covered by the 
Privacy Rule, to the extent that such information is individually 
identifiable.219 Further, HIPAA-covered entities may not use or 
disclose protected genetic information for underwriting purposes.220 
The Patient Protection and Affordable Care Act of 2010 (“ACA”) 
filled additional gaps, and as of January 1, 2014, patients with 
preexisting conditions, like SCD, could no longer be denied health 
insurance coverage.221 In addition, prophylactic measures such as 
pneumonia and influenza vaccinations—which are important for 
people living with SCD—are currently covered as preventative 
services.222 However, if successful, recent attempts to dismantle the 
ACA will undo the law’s preexisting conditions protections.223 
A. The Need for Protections Spurs GINA 
In the 1990s, genomic science was growing exponentially. As 
scientists, policymakers, and legislators realized the obvious clinical 
relevance of genomic medicine, they also understood that research 
participation by individuals to benefit our collective health would be 
met by fear that genetic research study participants would 
subsequently encounter genetic discrimination in the health insurance 
 
 217. Slaughter, supra note 112, at 42. 
 218. Id. at 42, 48. 
 219. 45 C.F.R. §	164.502(a)(5)(i) (2018). 
 220. Privacy in Genomics, NIH: NAT’L HUM. GENOME RES. INST. (Apr. 21, 2015), 
https://www.genome.gov/27561246/privacy-in-genomics/ [https://perma.cc/5Q98-SABK]. No 
such restrictions attach to the use or disclosure of PHI that has been de-identified. Id. De-
identification is often impermanent, due to insufficient proactive protections, and the 
documented ability of computer science hackers to re-identify previously de-identified 
information. Mats G. Hansson et al., The Risk of Re-Identification Versus the Need to 
Identify Individuals in Rare Disease Research, 24 EUR. J. HUM. GENETICS 1553, 1553 
(2016). 
 221. Patient Protection and Affordable Care Act, 42 U.S.C. §	18001(a), (d) (2012). 
 222. Cara V. James, On the Path to Health Equity: Improving the Quality of Sickle Cell 
Disease Care, CMS.GOV: CMS HEALTH EQUITY BLOG (Sept. 22, 2016), 
https://www.cms.gov/About-CMS/Agency-Information/OMH/about-cms-omh/blog/sickle-cell-
disease-care.html [https://perma.cc/FVV4-CA5Z]. 
 223. Laura Hercher & Anya E.R. Prince, Gene Therapy’s Field of Dreams: If You 
Build It, Will We Pay?, 97 N.C. L. REV. 1463, 1491 (2019). A recent victory for those who 
oppose the ACA came in Texas v. United States, 340 F. Supp. 3d 579 (N.D. Tex. 2018), 
when the Northern District of Texas issued a decision declaring the ACA 
unconstitutional. Id. at 619. Sixteen states and the District of Columbia, intervenors in the 
action, have appealed and continue to defend the ACA. Notice of Appeal at 1–2, Texas v. 
United States, 340 F. Supp. 3d. 579 (N.D. Tex. 2018) (No. 4:18-CV-00167-O).  
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sector and the workplace.224 In fact, 92% of Americans were 
concerned that results of genetic testing might be used for harmful 
purposes.225 Despite the uncertainty and complexity of genetic testing, 
some employers and health insurers perceived a benefit from 
obtaining genetic information.226 Reforms were urgently needed to 
address citizens’ concerns about the real threats of workplace and 
health insurance discrimination.227 Senator Edward Kennedy, a GINA 
cosponsor in the Senate, aptly stated: “Discrimination in health 
insurance and the fear of potential discrimination threaten both 
society’s ability to use new genetic technologies to improve human 
health and the ability to conduct the very research we need to 
understand, treat, and prevent genetic disease.”228  
As researchers worked to harness the potential of genetic 
medicine to improve understanding of diseases and develop new, 
personalized treatments, legislators began efforts to craft protections 
against genetic discrimination.229 In deliberating the need for a federal 
law that would protect private citizens from genetic discrimination, 
Congress considered evidence of targeted genetic discrimination 
against individuals in minority populations who carried genes 
associated with a specific genetic disease or risk; SCD among African 
Americans was one such disease.230 After years of diligence and 
 
 224. See Kathy L. Hudson, M.K. Holohan & Francis S. Collins, Keeping Pace with the 
Times – The Genetic Information Nondiscrimination Act of 2008, 358 NEW ENG. J. MED. 
2661, 2661, 2663 (2008); see also Protecting Workers from Genetic Discrimination: Hearing 
Before the Subcomm. on Health, Emp’t, Labor & Pensions of the H. Comm. on Educ. & 
Labor, 110th Cong. 33 (2007) [hereinafter Protecting Workers from Genetic 
Discrimination] (prepared statement of Karen H. Rothenberg, Dean and Marjorie Cook 
Professor of Law, University of Maryland School of Law) (“The tremendous promise of 
genomics is hamstrung by fear.”); Kathy L. Hudson, Prohibiting Genetic Discrimination, 
356 NEW ENG. J. MED. 2021, 2022 (2007) (explaining that fear of genetic discrimination 
also stymied patients’ willingness to undergo genetic tests recommended by their 
physicians or have results of such tests included in their medical records). 
 225. Protecting Workers from Genetic Discrimination, supra note 224, at 11 (prepared 
statement of the Hon. Louise McIntosh Slaughter). 
 226. Slaughter, supra note 112, at 44; see also Genetic Non-Discrimination: Examining 
the Implications for Workers and Employers: Hearing Before the Subcomm. on Emp’r-
Emp. Relations of the H. Comm. on Educ. & the Workforce, 108th Cong. 71 (2004) 
[hereinafter Genetic Non-Discrimination] (statement of National Workrights Institute) 
(“In a 2001 survey of U.S. firms almost 2% were currently conducting genetic tests for 
Sickle Cell and Huntington’s Disease, 14% were acquiring genetic information during 
workplace susceptibility testing and 20% reported requesting family medical histories 
containing information on the likelihood of disease.”). 
 227. See Hudson et al., supra note 224, at 2661. 
 228. Id. at 2662. 
 229. See id.  
 230. Expert Report of Paul A. Lombardo at 4, Lowe v. Atlas Logistics Grp. Retail 
Servs., No. 1:13-cv-02425-AT (N.D. Ga. June 5, 2015), ECF No. 70. 
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determination, GINA was signed into law by President George W. 
Bush.231 Senator Edward Kennedy proclaimed GINA “the first major 
new civil rights bill of the new century.”232 
B. GINA’s Protections 
 GINA’s purpose is to “‘establish[] a .	.	. uniform .	.	. standard’ of 
unacceptable use of genetic information .	.	. ‘to fully protect the public 
from discrimination and allay their concerns about the potential for 
discrimination, thereby allowing individuals to take advantage of 
genetic testing, technologies, research, and new therapies.’”233 GINA 
has two major parts. Title I, which prohibits genetic discrimination in 
health insurance, applies to employer-sponsored group health plans, 
health insurance issuers in group and individual marketplaces, 
Medigap insurance, and state and local nonfederal government 
plans.234 Title I expressly bans use or disclosure of genetic information 
for underwriting purposes but does not mandate coverage of any 
particular genetic test or treatment and does not prohibit medical 
underwriting based on current health status.235 Title II of GINA 
 
 231. Prior to GINA’s passage, by Executive Order signed by President Clinton, federal 
agencies were prohibited from discriminating against job applicants and employees based 
on genetic information. See generally Exec. Order No. 13,145, 65 Fed. Reg. 6877 (Feb. 10, 
2000). Dating back at least to 2001, President George W. Bush also supported legislation 
to end unfair genetic discrimination, stating:  
 
Genetic discrimination is unfair to workers and their families. It is unjustified—
among other reasons, because it involves little more than medical speculation. A 
genetic predisposition toward cancer or heart disease does not mean the 
condition will develop. To deny employment or insurance to a healthy person 
based only on a predisposition violates our country’s belief in equal treatment 
and individual merit. 
 
 The President’s Radio Address, 37 WEEKLY COMP. PRES. DOC. 963 (June 23, 2001). 
 232. Ben Feller, Bush Signs Anti-Discrimination Bill [GINA], CTR. FOR GENETICS & 
SOC’Y (May 21, 2008), https://www.geneticsandsociety.org/article.php?id=4096 
[https://perma.cc/SLY6-GN2S]. 
 233. Lowe v. Atlas Logistics Grp. Retail Servs. (Atlanta), LLC, 102 F. Supp. 3d 1360, 
1367 (N.D. Ga. 2015) (first alteration in original) (emphasis added). 
 234. Slaughter, supra note 112, at 56.  
 235. Id. HHS Standards for Privacy of Individually Identifiable Health Information, 
known as medical privacy regulations, provide protections against use and disclosure of all 
individually identifiable genetic information, but those regulations allow “use” of health 
information for insurance underwriting purposes. 45 C.F.R. §§	160.103, 164.502 (2018). 
GINA also amended the Employee Retirement Income Security Act of 1974. 29 U.S.C. 
§	1191b(d)(6)(B) (2012) (clarifying that protected genetic information includes “requests 
for, or receipt of genetic services, or participation in clinical research that includes genetic 
services by [an employee] or any family member [of the employee]”). The Public Health 
Service Act, Internal Revenue Code of 1986, and Title XVIII of the Social Security Act 
are also amended by GINA. Slaughter, supra note 112, at 56. Under GINA, health 
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makes it illegal to discriminate against employees or job applicants 
based on genetic information.236 The Department of Labor, the 
Department of Health and Human Services (“HHS”), and the 
Treasury Department have joint power to promulgate and enforce 
regulations relating to health insurance under GINA’s Title I.237 The 
EEOC oversees GINA’s Title II, which relates to employment 
discrimination.238 Under 42 U.S.C. §	2000ff-10, the EEOC 
promulgated a rule codified at 29 C.F.R. §	1635;239 the GINA rule 
defines “genetic test” with the exact language from the statute.240 The 
regulation goes further, though, and provides specific examples of 
genetic testing, including: “[c]arrier screening for adults using genetic 
analysis to determine the risk of conditions such as .	.	. sickle cell 
anemia.”241 The regulation notes that the list is not intended to be 
exhaustive.242  
1.  GINA and SCD 
As stated earlier, sickle cell anemia was among the first single-
gene mutations identified.243 In the 1970s, African Americans had 
been targeted for genetic testing for SCD and SCT. Their test results 
were not held in confidence, and stigmatization and discrimination in 
employment and health insurance coverage ensued.244 SCD has 
become a “racialized” genetic disease in that it has been cast as 
 
insurance issuers are prohibited from adjusting premiums or contribution amounts for 
group coverage on the basis of genetic information. 29 U.S.C. §	1182(b)(3)(A) (2012). And 
group health plans and health insurers are prohibited from denying coverage to a healthy 
individual or charging that individual higher premiums based solely on a genetic 
predisposition to specific diseases. Id. §	1182(b)(1). Further, Title I applies to data relating 
to genetic information in the context of family history and prohibits a health insurer from 
requesting or requiring participants to undergo genetic testing. 42 U.S.C. §	2000ff-1 (2012). 
 236. Id. Hiring, firing, job assignments, and promotions are examples of areas where 
genetic information discrimination is prohibited, and the bill extends beyond employers to 
include unions, employment agencies, and labor-management training programs. 
Slaughter, supra note 112, at 57. 
 237. See Genetic Information Nondiscrimination Act of 2008, Pub. L. No. 110-233, 
§	106, 122 Stat. 881, 905 (codified as amended in scattered sections of 42 U.S.C.). 
 238. See 42 U.S.C. §	2000ff-10 (2012). 
 239. See 29 C.F.R. §	1635.3(f)(1) (2018). 
 240. “[G]enetic test” is defined as “an analysis of human DNA, RNA, chromosomes, 
proteins, or metabolites that detects genotypes, mutations, or chromosomal changes.” 42 
U.S.C. §	2000ff(7)(A) (2012); §	1635.3(f)(1). 
 241. 29 C.F.R. §	1635.3(f)(2) (2018) (emphasis added). 
 242. Id. 
 243. See Slaughter, supra note 112, at 43.  
 244. See Hearing: Genetic Non-Discrimination, supra note 226, at 107–08 (statement of 
Karen H. Rothenberg, Dean and Marjorie Cook Professor of Law, University of 
Maryland School of Law); see also Slaughter, supra note 112, at 45. 
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belonging to a particular race, contrary to fact and science.245 
Therefore, with genetic variants like those present in SCT and SCD, 
concerns about discrimination are heightened. For this reason, GINA 
specifically names carriers for sickle cell anemia in its “Findings” 
section:  
[M]embers of a particular group may be stigmatized or 
discriminated against as a result of that genetic information. 
This form of discrimination was evident in the 1970s, which saw 
the advent of programs to screen and identify carriers of sickle 
cell anemia .	.	.	. State legislatures [enacted] discriminatory laws 
.	.	. and in the early 1970s began mandating genetic screening of 
all African Americans for sickle cell anemia, leading to 
discrimination and unnecessary fear.246 
2.  GINA’s Limitations 
As noted above, GINA has been described as the first civil rights 
legislation of the twenty-first century. Yet concern continues that 
genetic information will be used to “violate the privacy that surrounds 
familial relationships and medical care.”247 A number of studies 
document that underrepresented groups in research still have 
heightened concerns regarding privacy, including control over their 
genetic information.248  
Despite the “Findings” section’s reference to the SCD and SCT 
community’s experienced legacy of discrimination, GINA does not 
provide protection to those with genetic diseases, including SCD. For 
example, an individual’s diagnosed disease, disorder, or pathological 
condition, or any signs or symptoms of such conditions, are not 
covered genetic information under GINA, even if that condition has a 
genetic basis.249 GINA restricts its definition of “genetic test” to 
 
 245.  Ajunwa, supra note 213, at 86. 
 246. 42 U.S.C. §	2000ff cmt. 3 (Legislative Findings) (emphasis added). 
 247. Expert Report of Paul A. Lombardo, supra note 230, at 3.  
 248. Ellen W. Clayton et al., A Systematic Literature Review of Individuals’ 
Perspectives on Privacy and Genetic information in the United States, 13 PLOS ONE, no. 
e0204417, Oct. 31, 2018, at 1, 12.  
 249. See 42 U.S.C. §	2000ff-9 (2012); 29 C.F.R. §	1635.12(a) (2018); Ajunwa, supra note 
213, at 94. A disease, disorder, or pathological condition is considered “manifested” if the 
individual “has been or could reasonably be diagnosed with the disease, disorder, or 
pathological condition by a healthcare professional.” 29 C.F.R. §	1635.3(g) (2018). A 
disease, disorder or pathological condition is not considered manifested “if the diagnosis is 
based principally on genetic information.” Id. Health insurance regulations similarly have 
defined “manifestation.” Anya E.R. Prince & Benjamin E. Berkman, When Does an 
Illness Begin: Genetic Discrimination and Disease Manifestation, 40 J.L. MED. & ETHICS 
655, 661 (2012). Though GINA does not cover a condition’s diagnosis or signs or 
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analysis of human DNA, RNA, chromosomes, proteins, or 
metabolites that detect genotypes, mutations, or chromosomal 
changes.250 However, it does not prohibit other widely used tests, for 
example, those that measure complete blood counts, cholesterol, or 
liver function.251 This creates a “gray area for discrimination,” as a 
simple blood test may be used to detect genetic diseases like SCD.252 
Furthermore, GINA does not protect “analys[e]s of proteins or 
metabolites that are directly related to a manifested disease, disorder, 
or pathological condition that could reasonably be detected by a 
health care professional with appropriate training and expertise in the 
field of medicine involved.”253 Also, an employer does not violate 
GINA by using, acquiring, or disclosing medical information “that is 
not genetic information about a manifested disease, disorder, or 
pathological condition of an employee or member,” even if the 
disease, disorder, or pathological condition has or may have a genetic 
basis or component.254 These deficiencies give rise to calls by some 
scholars for a disparate impact theory of protection under GINA, 
which “would allow plaintiffs to show a pattern of employers turning 
away individuals known [or believed] to carry such genetic diseases 
from employment,” even if the employer had not subjected the 
potential employee to testing deemed to be “genetic testing” under 
GINA’s stringent definition.255  
One of its principal sponsors in the House viewed GINA as “an 
important step towards freedom from insidious discrimination,” but 
the effort is by no means finished.256 And “[j]ust as access to all civil 
 
symptoms of that diagnosis, the EEOC has made clear that such information is still subject 
to other laws that regulate the acquisition and use of medical information, such as Title I 
of the ADA. Id. at 661. 
 250. 29 C.F.R. §	1635.3(f)(3) (2018). 
 251. Id.; Ajunwa, supra note 213, at 94.  
 252. Ajunwa, supra note 213, at 94. These holes in protection expose individuals to 
“covert genetic discrimination.” Id.  
 253. Id. (alteration in original). 
 254. 29 C.F.R. §	1635.12(a) (2018) (emphasis added). 
 255. Ajunwa, supra note 213, at 94. But see Duru, supra note 77, at 286–87 (“M]any 
judges remain hostile towards the disparate impact theory of liability, which is unlikely to 
survive many more court challenges.”).  
 256. Slaughter, supra note 112, at 59. One notable limitation is that GINA provides no 
protection against genetic discrimination by insurers selling policies for life, disability, or 
long-term care insurance, or discrimination by creditors based on genetic information. 
Hudson et al., supra note 224, at 2662. “This [was] not the result of oversight: a strategic 
decision was made early on to recognize the very distinct markets, social purposes, risks of 
adverse selection, and bodies of relevant law governing these types of insurance.” Id. at 
2663. As of 2017, forty-eight states and the District of Columbia have instituted their own 
laws prohibiting genetic discrimination by health insurance providers, and thirty-five states 
and the District of Columbia have prohibitions against genetic discrimination in 
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rights developed in stages,” GINA represents “only a first step” 
toward protecting the American people from discrimination based on 
genetic information.257 The law is imperfect and does not provide as 
much protection as some organizations and families may have 
hoped,258 and even with GINA in place the risk of a “genetic 
underclass” persists.259 Gaps in legal protections make equitable 
access to gene-editing treatments all the more important, as GINA 
will not protect individuals with SCD against discrimination in the 
workplace or in obtaining insurance. This, and the tenuous status of 
ACA preexisting condition protections, leaves the SCD community 
with a pressing need for not only a cure but a cure that is affordable. 
Being blocked from workplace participation and affordable health 
care (which often is obtained through one’s workplace), the 
community experiences a heightened vulnerability and need for 
solutions. 
Perhaps the most striking of GINA’s limitations is that once an 
individual’s genetic condition manifests or is diagnosed, that person 
no longer qualifies for GINA protections.260 So, for example, in the 
 
employment. Genetic Discrimination and Other Laws, NIH: NAT’L HUM. GENOME RES. 
INST. (Apr. 17, 2017), https://www.genome.gov/27568503/genetic-discrimination-and-other-
laws [https://perma.cc/8VTT-TVG8]. Mississippi and Washington are the only two states 
that have not passed laws prohibiting genetic discrimination in health insurance. Id. Some 
states have bolstered GINA protections by including prohibitions against genetic 
discrimination in “other insurances,” including those for life, disability, and long-term care 
policies. Id. As of 2017, seventeen states have additional laws restricting the use of genetic 
information in determining coverage for life insurance, seventeen states for disability 
insurance, and eight states for long-term care insurance. Id. Three years after GINA’s 
passage, the state of California passed the California Genetic Information 
Nondiscrimination Act (“CalGINA”), which expands GINA’s protections by prohibiting 
genetic discrimination in emergency medical services, housing, mortgage lending, 
education, state-funded services, and public accommodation and also lowers the employee 
amount to five (from the more permissive fifteen-employee threshold under GINA). CAL. 
GOV’T CODE §§	1135, 12920 (West 2018); see also Slaughter, supra note 112, at 63. In 
2016, Maryland imposed restrictions on life insurance companies, prohibiting unfair 
discrimination between individuals of the same class and equal life expectancy, and made 
specific mention of SCT. MD. CODE ANN., INS. §	27-208 (Westlaw through legis. effective 
Apr. 30, 2019, from the 2019 Reg. Sess.). 
 257. Slaughter, supra note 112, at 59. 
 258. Hudson et al., supra note 224, at 2662. For example, it is argued that if diagnosed 
genetic illnesses had been included within GINA’s protections, this would have caused 
economic disruption in the individual health insurance market which, at that time, 
underwrote on the basis of diagnosed diseases. Id. at 2662–63. Further, from an ethics 
standpoint, it would have been “fundamentally unjust to treat people with genetic diseases 
differently from those whose diseases are nongenetic or have unknown causes.” Id. at 
2663. 
 259. Ajunwa, supra note 213, at 90.  
 260. See supra note 249 and accompanying text. 
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context of the SCD and SCT community, an infant testing positive for 
SCT is a carrier of a genetic variant but does not have the disease and, 
thus, is protected by GINA.261 By contrast, an infant who tests 
positive at birth for SCD seems to be stripped of GINA’s protections 
because he or she has a diagnosed genetic condition. As Keith Wailoo 
states, “[T]he experience of the illness varies greatly from one person 
to the next. In some, pain and infection are overwhelming and 
recurrent, and in others such symptoms are barely discernible.”262 But 
this fact is irrelevant under GINA, which appears to draw bright, 
unyielding lines. 
Currently, individuals facing discrimination based on SCD must 
rely on clever combinations of federal and state laws, other than 
GINA, to assert their rights.263 Legislation specifically extending 
protections to those with genetic diseases—manifested and/or 
diagnosed—is needed to meaningfully advance the cause of members 
of the SCD community who suffer discrimination in the workplace 
and in obtaining insurance, especially if ACA protections are 
eliminated. If federal legislators are unable or unwilling to implement 
changes, state legislators and governors can play a substantial role in 
bringing forth change. While GINA provides a baseline of protection 
at the national level, some states have crafted even broader 
safeguards to supplement those provided under GINA, although 
these state laws vary widely in scope, applicability, and degree of 
protection.264 GINA sets a floor of minimum protection against 
genetic discrimination; state laws with stricter protections are not 
preempted.265 
The law’s response when CRISPR technology successfully cures 
genetic disease will be noteworthy. Unless clarified through new 
legislation or regulations, the courts will need to address reconciling 
GINA’s approach to the manifested genetic disease with an outcome 
GINA did not anticipate: the cured genetic disease. What type of 
 
 261. See supra note 249 and accompanying text. As we learn more about sickle cell 
carrier status and other diseases with a recessive pattern of inheritance, in rare 
circumstances, having one allele may have clinical complications. Should this be 
considered “manifested disease” for purposes of GINA? We assert carrier status is not 
clinical manifestation of a genetic disease. 
 262. WAILOO, supra note 85, at 9. 
 263. For case law describing the legacy of discrimination and recognized patients’ 
rights, see supra Part III. 
 264. Genetic Discrimination and Other Laws, supra note 256. Some of these laws 
predated GINA, and some were enacted subsequent to GINA. Id. 
 265. Id.; see also Hudson et al., supra note 224, at 2662. For a discussion of more 
extensive state law protections, see text accompanying supra note 256. 
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proof will be necessary to restore an individual’s protection under 
GINA? These are among the questions the law will need to 
contemplate. But first, there are more salient questions regarding how 
best to achieve and ensure equitable access to SCD cures. For the 
SCD community, which historically has experienced health inequities, 
this is a critical concern. 
VI.  EQUITY AND GENOME EDITING 
Thus far, the Article has highlighted how gene editing is a source 
of hope for the SCD community, explored the community’s 
skepticism and fear in embracing that hope and examined reasons 
why the community might be distrustful of government agencies, 
researchers, and some health-care providers. The Article spotlighted 
instances of this community’s experienced history of discrimination 
and described the inadequacy of current legal protections. This part 
highlights additional concerns surrounding equitable access to gene 
editing in the context of SCD. It concludes by summarizing why 
equity concerns should be paramount in treatment and research 
efforts surrounding gene editing in SCD and then offers initial 
thoughts on how such equity concerns can remain central to future 
work. 
A. Disparity Diseases and Civil Rights 
SCD adversely impacts U.S. populations that already experience 
significant health disparities.266 Congress defined health disparities as 
“a significant disparity in the overall rate of disease incidence, 
prevalence, morbidity, mortality, or survival rates in the population as 
compared to the health status of the general population” in the 
Minority Health and Health Disparities Research and Education Act 
of 2000.267 Healthy People 2020 defines a health disparity as  
a particular type of health difference that is closely linked with 
social or economic disadvantage. Health disparities adversely 
affect groups of people who have systematically experienced 
greater social or economic obstacles to health based on their 
racial or ethnic group, religion, socioeconomic status, gender, 
mental health, cognitive, sensory, or physical disability, sexual 
 
 266. Michele Goodwin, Revisiting Death: Implicit Bias and the Case of Jahi McMath, 
HASTINGS CTR. REP., Nov.–Dec. 2018, S77, S78–S79.  
 267. 42 U.S.C. §	285t(d)(1) (2012). 
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orientation, geographic location, or other characteristics 
historically linked to discrimination or exclusion.268  
As stated earlier, African ancestral populations have the highest rates 
of SCD in the United States and, overall, also experience greater 
health inequities and health disparities.269 Although SCD is far more 
prevalent than other rare genetic diseases, historically, less funding, 
research, and overall attention has been allocated for SCD 
treatment.270  
Addressing health disparities is a civil rights issue. “Civil rights 
laws and their enforcement are social determinants of health because 
they affect other social determinants of health .	.	. such as education, 
housing, transportation, employment, and the system of justice 
.	.	.	.”271 As such, civil rights laws “causally affect the societal 
distribution of resources that in turn affect disease, injury, and 
health.”272 Health equity is the principle to address disparities in 
health, striving for the highest possible standard of health for all.273 
The disparities that exist in the treatment of SCD must be 
contextualized in the development of the human genome-editing 
technology aimed at the disease’s treatment and prevention. If 
researchers, biotechnology firms, and policymakers are not mindful of 
this context, we are concerned that this disease, burdened with the 
legacy of neglect, will not benefit equally in genetic editing. 
 
 268. U.S. DEP’T OF HEALTH & HUM. SERVS., THE SECRETARY’S ADVISORY 
COMMITTEE ON NATIONAL HEALTH PROMOTION AND DISEASE PREVENTION 
OBJECTIVES FOR 2020, at 28 (2008), https://healthypeople.gov/sites/default/files/
PhaseI_0.pdf [https://perma.cc/PJN2-LTP4]. 
 269. CDC Health Disparities & Inequalities Report, CENTERS FOR DISEASE CONTROL 
& PREVENTION, https://www.cdc.gov/minorityhealth/CHDIReport.html [https://perma.cc/
J7RX-JY7A]. 
 270. Scott, supra note 98, at 731. 
 271. R.A. Hahn, B.I. Truman & D.R. Williams, Civil Rights as Determinants of Public 
Health and Racial and Ethnic Health Equality: Health Care, Education, Employment, and 
Housing in the United States, 4 SSM POPULATION HEALTH 17, 17–18 (2018). 
 272. Id.  
 273. Paula Braveman, What Are Health Disparities and Health Equity? We Need to Be 
Clear, 129 PUB. HEALTH REP. 5, 6, 7 (2014) (“Health equity and health disparities are 
intertwined. Health equity means social justice in health (i.e., no one is denied the 
possibility to be healthy for belonging to a group that has historically been 
economically/socially disadvantaged). Health disparities are the metric we use to measure 
progress toward achieving health equity. A reduction in health disparities (in absolute and 
relative terms) is evidence that we are moving toward greater health equity.”). 
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B. Ensuring Equitable Access Globally and the Legal and Economic 
Obstacles 
Equity and fairness in access to new curative genetic therapies is 
not limited to the United States and Europe. It is important to note 
the extensive burden of SCD outside of high-income countries. 
Estimates of infants born with sickle cell anemia annually range from 
300,000 to 400,000.274 The vast majority of these births occur in three 
countries: Nigeria, the Democratic Republic of the Congo, and 
India.275 Approximately 1000 babies are born with SCD in Africa 
every day and more than half will die before their fifth birthday.276 
Piel and colleagues report that the global burden is increasing and 
highlight the need for low- and middle-income countries to develop 
national policies for newborn screening, public health planning, and 
treatment.277 Researchers contemplating the potential of human 
genome editing as a genetic curative strategy for SCD must also 
question the impact for low- and middle-income countries 
experiencing the greatest burden of this disease. Low- and middle-
income countries are even less equipped to conduct (ex vivo) human 
genome editing, especially when considering the unsustainable cost 
anticipated in high-income countries.278 
However, leaders in global health and development are looking 
to use CRISPR and other genome-editing technologies to help 
humanity overcome some of its biggest and most persistent 
challenges.279 For example, the director of the NIH, Francis Collins, 
 
 274. Piel et al., Sickle Cell Disease, supra note 25, at 1561. 
 275. Id. 
 276. World Sickle Cell Day, SICKLE CELL DISEASE COALITION, 
http://www.scdcoalition.org/priorities/global.html [https://perma.cc/S9QP-YGGJ]. 
 277. Piel et al., Global Burden, supra note 30, at 9. 
 278. “Currently, most gene therapy trials for [SCD] are ex vivo. However, ex vivo gene 
therapy is a complicated, multi-step process that takes weeks and requires 
hospitalization.” Alice Dickow, The Gates Foundation Backs Gene Editing Research to 
Treat a Devastating Disease, INSIDE PHILANTHROPY (Mar. 2, 2019), 
https://www.insidephilanthropy.com/home/2019/3/3/the-gates-foundation-backs-gene-editing-
research-to-treat-a-devastating-disease [https://perma.cc/RU9M-Q7H5]. Researchers are 
developing methods that allow in vivo gene-therapy applications for SCD in areas of the 
world where health-care systems are less developed than in the United States and Europe. 
Id.  
 279. See, e.g., Bill Gates, Gene Editing for Good: How CRISPR Could Transform 
Global Development, FOREIGN AFF. (Apr. 10, 2018), https://www.foreignaffairs.com/
articles/2018-04-10/gene-editing-good [https://perma.cc/FSQ5-BKJC] (“The technology is 
making it much easier for scientists to discover better diagnostics, treatments, and other 
tools to fight diseases that still kill and disable millions of people every year, primarily the 
poor. It is also accelerating research that could help end extreme poverty by enabling 
millions of farmers in the developing world to grow crops and raise livestock that are more 
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discussed how genome editing may accelerate a cure for SCD, noting 
that  
[t]he complicated, high-tech procedures .	.	. may not be practical 
for a very long time in places like sub-Saharan Africa. That’s 
one reason why NIH recently launched a new effort to speed 
the development of safe, effective genome-editing approaches 
that could be delivered directly into a patient’s body (in vivo), 
perhaps by infusion of the CRISPR gene editing apparatus.280 
Moreover, at the end of 2018, the Bill and Melinda Gates Foundation 
awarded a $1.5 million grant to Boston Children’s Hospital to 
research and develop gene-therapy treatment for SCD with the long-
term goal of making the treatment available to patients in developing 
countries.281 
Exploring the legal, policy, and social implications of genome 
editing includes grappling with this question of whether low- and 
middle-income countries and their citizens will benefit from this new 
technology. If the goal is truly to benefit those suffering from SCD, 
the scientific agenda must develop and implement an international 
framework for somatic human genome editing that is accessible to the 
millions of sub-Saharan African and Indian people with this disease.  
However, patent disputes and the projected exorbitant costs of 
treatment may hinder progress with respect to developing and 
perfecting CRISPR biotechnology.  
1.  Legal Disputes Could Slow Clinical Trials and Treatment 
 While there is optimism about the scientific community’s 
commitment to finding a cure, patent litigation between leaders282 in 
 
productive, more nutritious, and hardier. New technologies are often met with skepticism. 
But if the world is to continue the remarkable progress of the past few decades, it is vital 
that scientists, subject to safety and ethics guidelines, be encouraged to continue taking 
advantage of such promising tools as CRISPR.”). 
 280. Collins, supra note 62. 
 281. David A. Williams, Boston Children’s Hospital Receives Grant for Sickle Cell 
Disease Research, HEALIO (Dec. 30, 2018), https://www.healio.com/hematology-oncology/
hematology/news/online/%7B9ba22126-f234-457d-bfd7-23fef382e43c%7D/boston-childrens-
hospital-receives-grant-for-sickle-cell-disease-research [https://perma.cc/8P9K-29DT] (“While 
gene therapies are currently confined to a few research hospitals in the U.S. and other 
developed countries, our long-term goal is to make this treatment available to patients in 
developing countries—and we have already begun to think about how to translate this 
specialized, potentially curative therapy.”). 
 282. The University of California, Berkeley (“UC Berkeley”), with the University of 
Vienna and Emmanuelle Charpentier, and the Broad Institute, with MIT and Harvard, 
are parties involved in the litigation over patent rights to the CRISPR-Cas9 gene-editing 
technology. See Univ. of Cal. v. Broad Inst. Inc., 903 F.3d 1286, 1286 (Fed. Cir. 2018).  
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the CRISPR-Cas9 field has complicated matters in the United 
States283 and in Europe.284 Final outcomes of these matters are 
critically important because they determine who holds which rights, 
who may decide on and implement future research with the 
biotechnology, and who may grant licenses for its use. Most 
importantly, patent litigation could potentially stall development of 
curative genetic therapies. 
However, forward momentum is evident in clinical trials. For 
example, in April 2018, sponsor CRISPR Therapeutics and 
collaborator Vertex submitted an Investigational New Drug (“IND”) 
Application to the FDA for the treatment of adults with SCD using 
CTX001 CRISPR technology.285 In late May 2018, the FDA placed a 
 
 283. See id. On September 10, 2018, the Federal Circuit upheld the U.S. Patent & 
Trademark Patent Trial and Appeal Board (“PTAB”) determination in favor of the Broad 
Institute. Id. at 1296. The Federal Circuit held that though Doudna (of UC Berkeley) and 
Charpentier (of the University of Vienna) were first to publish their CRISPR-Cas9 
findings, Doudna & Charpentier, supra note 22, demonstrating that the isolated elements 
of the CRISPR-Cas9 system could be used in vitro in a noncellular experimental 
environment, the Broad researchers’ February 2013 article described use of CRISPR-Cas9 
in a human cell line. Id. at 1289. A distinction made by the PTAB is that CRISPR-Cas 
systems occur naturally in prokaryotes such as bacteria but have not been found to 
naturally exist in eukaryotes, such as plants and animals. Id. The court found that 
substantial evidence supported the PTAB’s determination that, given the differences in 
eukaryotic cells and prokaryotic systems, a person of ordinary skill in the art would not 
have had a reasonable expectation of success in applying the CRISPR-Cas9 system in 
eukaryotic cells. Id. at 1290, 1296. The court agreed with the PTAB that UC Berkeley’s 
claims to the use of CRISPR-Cas9 did not “render obvious” Broad’s claims to its use in 
eukaryotes. Id. The Federal Circuit noted that this position could be supported in the 
record. Id. at 1294. “The prior art contained a number of techniques that had been used 
for adapting prokaryotic systems for use in eukaryotic cells, obstacles adopting other 
prokaryotic systems had been overcome, and [the UC Berkeley team] suggested using 
those techniques to implement CRISPR-Cas9 in eukaryotes.” Id. The court, however, 
went on to note that its function was appellate in nature and that it was not at liberty to 
reweigh the evidence. Id. “It is not our role to ask whether substantial evidence supports 
fact-findings not made by the Board, but instead whether such evidence supports the 
findings that were in fact made.” Id. For an excellent update on the Broad Institute 
litigation, see Sharon Begley, University of California to be Granted Long-Sought CRISPR 
Patent, Possibly Reviving Dispute with the Broad Institute, STAT: BIOTECH (Feb. 8, 2019), 
https://www.statnews.com/2019/02/08/the-university-of-california-gets-its-key-crispr-patent 
[https://perma.cc/4JHD-XMBJ].  
 284. See EP2800811 – Methods and Compositions for RNA-Directed Target DNA 
Modification and for RNA-Directed Modulation of Transcription, EUR. PAT. REG. (Dec. 
26, 2018), https://register.epo.org/application?number=EP13793997&lng=en&tab=main 
[https://perma.cc/8977-6BU4]. The same plaintiffs that were unsuccessful in the Broad 
Institute litigation prevailed in their European patent challenge against the same 
defendants before the European Patent Office and were granted a broad European patent 
for CRISPR-Cas9. Id.; see also Broad Inst., 903 F.3d at 1286.  
 285. CRISPR Therapeutics and Vertex Provide Update on FDA Review of 
Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease, 
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hold on the proposed clinical trial, but that hold was lifted by October 
2018.286 The FDA had certain questions that it required the sponsors 
to resolve before approval of the Phase I-II trial but has now accepted 
the IND Application and will allow the early-phase clinical trial to 
proceed.287 The sponsors also have obtained approvals of clinical trial 
applications in multiple countries for both β-thalassemia and SCD.288 
At the December 2018 American Society of Hematology Annual 
Meeting, a team of scientists reported that the CRISPR technology 
data shows that the “BCL11A enhancer editing approach[] .	.	. is a 
practicable therapeutic strategy to produce durable HbF induction in 
SCD and β-thalassemia.”289 Genome editing to increase HbF has the 
potential to alleviate transfusion requirements for β-thalassemia 
patients and painful and debilitating sickle crises for sickle cell 
patients.290 
2.  Costs and Who Will Pay? 
Affordability is a key consideration when making decisions 
about advancing genetic science. Particularly, is it worth it to invest in 
converting the science into therapies for which we will have to pay 
significant sums of money?291 This is a major concern of the SCD 
community. It is also a worry of legislators in states concerned about 
 
CRISPR THERAPEUTICS (May 30, 2018), https://globenewswire.com/news-release/2018/05/
30/1514301/0/en/CRISPR-Therapeutics-and-Vertex-Provide-Update-on-FDA-Review-
of-Investigational-New-Drug-Application-for-CTX001-for-the-Treatment-of-Sickle-Cell-
Disease.html [https://perma.cc/6FEU-SVY8] [hereinafter Update on FDA Review]. 
 286. Id.; CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold 
on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell 
Disease, CRISPR THERAPEUTICS (Oct. 10, 2018), https://globenewswire.com/news-
release/2018/10/10/1619581/0/en/CRISPR-Therapeutics-and-Vertex-Announce-FDA-Has-
Lifted-the-Clinical-Hold-on-the-Investigational-New-Drug-Application-for-CTX001-for-the-
Treatment-of-Sickle-Cell-Disease.html [https://perma.cc/SD4C-ETAX] [hereinafter 
CRISPR Therapeutics]; Alex Keown, FDA Lifts Clinical Hold; Green-Lights Vertex and 
CRISPR’s Sickle Cell Gene Therapy Trial, BIOSPACE (Oct. 11, 2018), 
https://www.biospace.com/article/fda-lifts-clinical-hold-green-lights-vertex-and-crispr-s-
sickle-cell-gene-therapy-trial/ [https://perma.cc/Z2A3-TSP9]. 
 287. CRISPR Therapeutics, supra note 286.  
 288. See Pipeline: Tackling a Range of Diseases with Different Approaches, CRISPR 
THERAPEUTICS, http://www.crisprtx.com/programs/pipeline [https://perma.cc/2PVE-JCVY]. 
 289. Am. Soc’y of Hematology, 3482 Highly Efficient Therapeutic Gene Editing of 
BCL11A Enhancer in Human Hematopoietic Stem Cells from ß-Hemoglobinopathy 
Patients for Fetal Hemoglobin Induction, ASH HOME (Dec. 2, 2018), https://ash.confex.com/
ash/2018/webprogram/Paper119365.html [https://perma.cc/SF3G-5TNX].  
 290. Update on FDA Review, supra note 285.  
 291. Erika Check Hayden, Gene Therapies Pose Million-Dollar Conundrum, 534 
NATURE 305, 305 (2016). 
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an inability to cover costs of available treatments.292 While new 
treatments for SCD and other serious diseases are great news for 
patients, even called “a Renaissance for treatments of long-
untreatable illnesses,” states may have some very difficult decisions to 
make.293 One cost-covering solution on the rise is a deal brokered 
between drug companies and insurers, known as “pay for 
performance,” whereby insurer payments are tied to a medicine’s 
actual performance; if patients fail to reach some pre-agreed-upon 
therapeutic response or the insurer ends up paying more than it has 
budgeted, the pharmaceuticals manufacturer refunds money to the 
insurer.294 Such deals are estimated to be in play in fourteen countries, 
mostly in the United States and Europe but also in middle-income 
countries, including Brazil.295 
Some scientists are exuberant about the potential for CRISPR in 
treating classic genetic diseases like SCD, believing that CRISPR not 
only will be transformative but also will make gene editing “cheap, 
easy and accessible, and therefore more common.”296 According to 
bioethicist Mildred Cho, however, even if CRISPR proves successful 
in clinical trials, the actual treatment will be cost prohibitive for many 
patients.297 Emphasizing the significant differences between 
undergoing gene-therapy treatment and taking a pill from a 
pharmacy, Cho states: “It’s more like getting an organ transplant. It’s 
a very complex procedure. Cancer immunotherapy already costs in 
the hundreds of thousands of dollars per year. There’s no way that 
gene-edited treatments are going to be any less expensive.”298 
With any CRISPR technology approved for use in treating SCD, 
there will be no existing approved drugs that work similarly, thus 
there may be little competition or incentive for companies to keep 
prices affordable.299 This is a major reason why there should be some 
type of agreement, understanding, or bargain between the SCD 
community and pharmaceutical companies that study CRISPR 
technology in clinical trials using volunteers from the sickle cell 
 
 292. Michael Booth, Effective But Very Expensive Drugs Are Forcing State Medicaid 
Directors to Make Some Tough Decisions, NAT’L CONF. ST. LEGISLATURES (Feb. 1, 
2017), http://www.ncsl.org/bookstore/state-legislatures-magazine/effective-but-expensive-
drugs-are-beyond-the-reach-of-many.aspx [https://perma.cc/BNG3-E7KV]. 
 293. Id. 
 294. Hayden, supra note 291, at 306. 
 295. Id. Data gathering and sharing centers are part of these arrangements. See id. 
 296. Shwartz, supra note 11, at 27.  
 297. Id. at 26.  
 298. Id.  
 299. Hayden, supra note 291, at 306. 
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community. These patients, and those in their community, must reap 
lasting benefits from any positive discoveries in research that they 
help to move forward. 
One option that may foster equitable access can be seen in 
public-private partnerships. Through public-private partnerships, 
philanthropic foundations commit resources to diseases or causes and 
act as facilitators in brokering agreements and negotiating promises 
of affordability and access.300 Recently, the Duke Charitable 
Foundation has funded the Critical Path Institute (“C-Path”) for 
development of advances in therapies for SCD.301 C-Path has a public-
private partnership with the FDA and an established record of 
building consortia to speed development of novel medical therapies 
for patients suffering from various diseases and conditions.302 The 
Duke Charitable Foundation lists sickle cell patient advocacy groups 
as stakeholders that will be part of the conversation.303 Hopefully, 
affordability and access—both initially and long-term—will be central 
to the discussion.  
Another, more mature C-Path endeavor, in collaboration with 
The Bill & Melinda Gates Foundation, is an initiative to develop 
effective treatments for Tuberculosis.304 That program specifically 
addresses concerns about the “dire need for faster-acting drugs to 
treat TB in all its forms that are effective, affordable, and 
accessible.”305 Other disease-specific initiatives are the ACT Initiative 
of the National Hemophilia Foundation306 and the Kidney Innovation 
 
 300. See, e.g., Press Release, Critical Path Inst., Doris Duke Charitable Foundation 
Awards Grant to Critical Path Institute to Advance Therapies for Sickle Cell Disease 
(Sept. 6, 2018), https://c-path.org/doris-duke-charitable-foundation-awards-grant-to-
critical-path-institute-to-advance-therapies-for-sickle-cell-disease/ [https://perma.cc/8BN3-
E2KH]. 
 301. Id. 
 302. Id. 
 303. Id. 
 304. Critical Path to TB Drug Regimens, CRITICAL PATH INST., https://c-path.org/
programs/cptr/ [https://perma.cc/LUT4-SRYG]. 
 305. Id. 
 306. The National Hemophilia Foundation implemented the ACT initiative with 
numerous partners from the biopharmaceuticals industry “to meet the imperative need to 
build [the] national capacity to maintain, and achieve where lacking, access to care for 
people with bleeding disorders.” The ACT Initiative, NAT’L HEMOPHILIA FOUND., 
https://www.hemophilia.org/About-Us/Access-to-Care-Today-Achieving-Cures-Tomorrow 
[https://perma.cc/HDK9-N8ZH]. The National Hemophilia Foundation defines access as 
follows: “[a]dherence to state-of-the-art standards of care, [a]ccess to hemophilia 
treatment centers (HTCs), [a]ccess to treatment products appropriate for the individual, 
and [a]dequate reimbursement for these life-saving therapies.” Id. 
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Accelerator (“KidneyX”).307 These more established programs and 
their emphasis on affordability and access can serve as examples as 
the newer SCD C-Path moves forward. 
CONCLUSION 
The promise of genome editing to address the burden of SCD is 
profound. The possibility that it will cause harm and will not 
equitably benefit those living with SCD in high-income countries, 
such as the United States, is real. With an eye toward ensuring 
equitable access, scientists, ethicists, economists, lawyers, and 
policymakers must develop new approaches to implement this new 
and expensive treatment in a population recognized to have been 
underserved. 
The stakes are high. The challenge is to foresee obstacles to 
access and affordability now, as Phase I clinical trials are being 
conducted, so that the SCD community is not left with a solution and 
no means of using it to solve this life-and-death problem. Currently, 
in low-income countries with the highest burden of SCD, the 
potential to benefit from genetic curative therapies and genome 
editing is unrealistic when those countries do not even have resources 
to implement newborn screening and preventive care.308 If the United 
States and other scientifically advanced countries are able to get the 
science right, we can and must share our knowledge and resources 
with low-income countries carrying the highest burdens of the 
disease. 
The National Academies of Sciences 2017 Report identified 
seven principles that should undergird the oversight systems, research 
on, and eventual clinical uses of human genome editing: (1) 
promoting well-being, (2) transparency, (3) due care, (4) responsible 
science, (5) respect for persons, (6) fairness, and (7) transnational 
 
 307. The Kidney Innovation Accelerator (KidneyX) is a public-private partnership 
designed to accelerate innovation in prevention, diagnosis, and treatment of kidney 
disease. HHS Announces Kidney Innovation Accelerator at ASN Kidney Week 2017, ASN 
(Jan. 9, 2018), https://www.asn-online.org/news/item.aspx?ID=144 [https://perma.cc/
RBX6-8TYY]. “The Accelerator will establish a public-private innovation fund capable of 
seeding and accelerating not just incremental improvements in treating kidney disease, but 
will foster real breakthroughs in dialysis and other treatments for kidney disease.” Id. In 
order to ensure that the path to commercialization is “straight and clear,” the Accelerator 
will bring together key components of HHS, notably the FDA, CMS, and the NIH. Id. 
 308. Lewis Hsu et al., White Paper: Pathways to Progress in Newborn Screening for 
Sickle Cell Disease in Sub-Saharan Africa, 6 J. TROPICAL DISEASES, no. 1000260, July 10, 
2018, at 1, 5; Bertin Tshimanga Kadima et al., High Rate of Sickle Cell Anaemia in Sub-
Saharan Africa Underlines the Need to Screen All Children with Severe Anaemia for the 
Disease, 104 ACTA PAEDIATRICA 1269, 1272 (2015).  
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cooperation.309 Each principle is essential to implementation of 
genome editing for SCD. The first five reflect requirements or 
aspirations clearly articulated in existing U.S. laws and policies 
relating to human subjects research. The last two, fairness and 
transnational cooperation, more easily have been bypassed in the race 
to develop new treatments for ailments in high-income countries. 
The future will be bright for those who carry the burden of SCD 
as an everyday life experience .	.	. provided that we prioritize the 
development of strategies to equitably integrate these new curative 
genetic therapies. With commitment, cooperation, and careful 
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